

# British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017\*

K.E. Harman,<sup>1</sup> D. Brown,<sup>2</sup> L.S. Exton,<sup>3</sup> R.W. Groves,<sup>4</sup> P.J. Hampton,<sup>5</sup> M.F. Mohd Mustapa,<sup>3</sup> J.F. Setterfield<sup>4,6</sup> and P.D. Yesudian<sup>7</sup>

<sup>1</sup>University Hospitals Leicester, Leicester Royal Infirmary, Infirmary Square, Leicester, LE1 5WW, U.K.

<sup>2</sup>St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, U.K.

<sup>3</sup>British Association of Dermatologists, Willan House, 4 Fitzroy Square, London W1T 5HQ, U.K.

<sup>4</sup>St. John's Institute of Dermatology, King's College London, Guy's Campus, Great Maze Pond, London SE1 9RT, U.K.

<sup>5</sup>Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, Tyne and Wear NE1 4LP, U.K.

<sup>6</sup>Mucosal & Salivary Biology Division, King's College London Dental Institute, Guy's Campus, Great Maze Pond, London SE1 9RT, U.K.

<sup>7</sup>Wrexham Maelor Hospital, Croesnewydd Road, Wrexham LL13 7TD, U.K.

## Correspondence

Karen Harman.

E-mails: karenharman@doctors.org.uk; guidelines@bad.org.uk

## Accepted for publication

27 July 2017

## Funding sources

Development of this guideline has been funded independently by the British Association of Dermatologists.

## Conflicts of interest

None declared.

K.E.H., D.B., R.W.G., P.J.H., J.F.S. and P.D.Y. are members of the guideline development group, with technical support provided by L.S.E. and M.F.M.M.

This is an updated guideline prepared for the British Association of Dermatologists (BAD) Clinical Standards Unit, which includes the Therapy & Guidelines (T&G) Subcommittee. Members of the Clinical Standards Unit who have been involved are P.M. McHenry (Chair T&G), K. Gibbon, D.A. Buckley, T.A. Leslie, E.C. Mallon, S. Wakelin, S. Ungureanu, R.Y.P. Hunasehally, M. Cork, G.A. Johnston, J. Natkunara-jah, F.S. Worsnop, N. Chiang, C.E. Duarte Williamson, J. Donnelly (British National Formulary), C. Saunders (British Dermatological Nursing Group), A.G. Brain (BAD Scientific Administrator), L.S. Exton (BAD Information Scientist) and M.F. Mohd Mustapa (BAD Clinical Standards Manager).

Produced in 2003 by the British Association of Dermatologists; reviewed and updated 2017.

\*Plain language summary available online

DOI 10.1111/bjd.15930



NICE has accredited the process used by the British Association of Dermatologists to produce guidelines. The renewed accreditation is valid until 31 May 2021 and applies to guidance produced using the process described in updated guidance for writing a British Association of Dermatologists clinical guidance – the adoption of the GRADE methodology 2016. The original accreditation term began on 12 May 2010. More information on accreditation can be viewed at [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

## 1.0 Purpose and scope

The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the management of pemphigus vulgaris (PV). The document aims to update and expand on the previous guidelines by (i) offering an appraisal of all relevant literature from January 2000 up to May 2016, focusing on any key developments; (ii) addressing important, practical, clinical questions relating to the primary guideline objective; (iii) providing guideline recommendations with, where appropriate, some health economic implications and (iv) discussing potential developments and future directions.

The guideline is presented as a detailed review with highlighted recommendations for practical use in the clinic (see Tables 1 and 4), in addition to an updated patient information leaflet (available on the BAD website, <http://www.bad.org.uk/for-the-public/patient-information-leaflets>).

### 1.1 Exclusions

This guideline does not cover other forms of pemphigus.

## 2.0 Stakeholder involvement and peer review

The Guideline Development Group (GDG) consisted of consultant dermatologists and a clinical nurse specialist in medical dermatology. One of the dermatologists is also an oral medicine specialist. The draft document was circulated to the BAD membership, the British Dermatological Nursing Group, the Primary Care Dermatological Society, the Pemphigus Vulgaris Network and PEM Friends (U.K.) for comments, which were actively considered by the GDG, and peer reviewed by the Clinical Standards Unit of the BAD (made up of the T&G Subcommittee) prior to publication.

## 3.0 Methodology

This set of guidelines has been developed using the BAD recommended methodology<sup>1</sup> with reference to the Appraisal of

Guidelines Research and Evaluation (AGREE II) instrument ([www.agreetrust.org](http://www.agreetrust.org)).<sup>2</sup> Recommendations were developed for implementation in the U.K. National Health Service (NHS) using a process of considered judgement based on the evidence. The PubMed, MEDLINE, Embase and LILACS databases were searched for PV from January 2000 up to May 2016; the search terms and strategies are detailed in Appendix S1 (see Supporting Information). Additional relevant references were also isolated from citations in the reviewed literature. All identified titles were screened, and those relevant for first-round inclusion were selected for further scrutiny. The abstracts for the shortlisted references were then reviewed by the GDG and the full papers of relevant material obtained; disagreements in the final selections were resolved by discussion with the entire GDG. The structure of the 2003 guidelines was then discussed and re-evaluated, with headings and subheadings decided; different coauthors were allocated separate subsections. Each coauthor then performed a detailed appraisal of the selected literature, with discussions within the GDG to resolve any issues. All subsections were subsequently collated, circulated within the GDG and edited to produce the final guidelines.

#### 4.0 Limitations of the guideline

This document has been prepared on behalf of the BAD and is based on the best data available when the document was prepared. It is recognized that under certain conditions it may be necessary to deviate from the guidelines and that the results of future studies may require some of the recommendations herein to be changed. Failure to adhere to these guidelines should not necessarily be considered negligent, nor should adherence to these recommendations constitute a defence against a claim of negligence. Limiting the review to English-language references was a pragmatic decision, but the authors recognize this may exclude some important information published in other languages.

#### 5.0 Plans for guideline revision

The proposed revision for this set of recommendations is scheduled for 2022; where necessary, important interim changes will be updated on the BAD website.

#### 6.0 Background

PV is an acquired autoimmune disease in which immunoglobulin G (IgG) antibodies target desmosomal proteins to produce intraepithelial, mucocutaneous blistering. Desmoglein 3 is the major antigen, but 50–60% of patients have additional antibodies to desmoglein 1, the antigen targeted in pemphigus foliaceus (PF).<sup>3–5</sup> Although the pathogenesis of PV is complex, involving multiple pathways,<sup>6</sup> the underlying antibody profile is a major determinant of the clinical phenotype of PV.<sup>5,7,8</sup>

The average mortality of PV was 75% before the introduction of corticosteroids in the early 1950s.<sup>9</sup> This figure may be

an underestimate due to the lack of diagnostic criteria, and inclusion of all subtypes of pemphigus and of other blistering disorders such as bullous pemphigoid, which have a better prognosis. However, not all cases of PV have such a dismal prognosis. Studies differentiating the clinical phenotypes have shown a lower mortality in patients with predominantly mucosal PV (1–17%) compared with those with mucocutaneous PV (8–42%).<sup>10–12</sup> Mucocutaneous PV tends to be a more severe disease, proving slower to respond to treatment and less likely to achieve remission off-treatment than purely mucosal PV.<sup>13</sup>

#### 6.1 Clinical presentation

The diagnosis of PV should be suspected in any patient with mucocutaneous erosions or blisters. The oral mucosa is the first site of involvement in the majority of cases, and PV may remain confined to the mucosal surfaces or extend to involve the skin (average lag period of 4 months).<sup>14–16</sup> Diagnostic delay is very common when PV is confined to the oral mucosa.<sup>17</sup> A minority of patients will present with cutaneous erosions, but oral erosions will, eventually, occur in most cases. PV presents across a wide age range with peak frequency in the third to sixth decades.

#### 7.0 Laboratory diagnosis

Perilesional skin biopsies should be taken for histology and direct immunofluorescence (DIF). In patients with isolated oral disease, a histology specimen should be taken from perilesional mucosa and a DIF sample taken from an uninvolved area, ideally from the buccal mucosa.<sup>18</sup> Suprabasal acantholysis with blister formation is highly suggestive of PV, but the diagnosis should be confirmed by the characteristic deposition of IgG and/or complement on the cell surfaces of epithelial keratinocytes. Indirect immunofluorescence (IIF) is less sensitive than DIF<sup>19–21</sup> but may be helpful if a biopsy is difficult, for example in children and uncooperative adults.

Commercial enzyme-linked immunosorbent assays (ELISAs) are available for direct measurement of desmoglein 1 and desmoglein 3 antibodies in serum. They potentially offer advantages over IIF, such as increased sensitivity, but are not helpful in cases in which there are other antigens.<sup>22–24</sup> Therefore, IIF and ELISA should be considered complementary and DIF remains the gold-standard diagnostic investigation.<sup>25</sup> Five millilitres of blood is sufficient for both IIF and ELISA. Saliva is potentially a useful alternative to serum for ELISA; there is emerging evidence that desmoglein 3 IgG is detectable in saliva by ELISA with a similar sensitivity to serum (61% saliva vs. 74% serum).<sup>26</sup>

In patients with oral pemphigus, an intraoral biopsy is optimum, but IIF or DIF on a skin biopsy may suffice. One study showed that the sensitivity of DIF was 71% in oral biopsies compared with 61% in normal skin taken from 28 patients with oral PV.<sup>27</sup> Another study reported that the sensitivity of DIF was 89% in oral biopsies compared with 85% for IIF.<sup>15</sup> If

there are no skin lesions and a sample for DIF is to be taken from the oral mucosa, the buccal mucosa can be exposed by everting the cheek, placing the thumb at the commissure and reflecting the corner of the mouth, applying external pressure on the cheek with the index finger to present the buccal mucosa.

The transport medium into which samples for DIF are placed varies, including saline, Michel's medium and snap freezing in liquid nitrogen.<sup>28</sup> Liquid nitrogen gives good preservation of immunoreactants but has practical disadvantages. However, it has been shown in one study using matched biopsy specimens that transportation in saline, for up to 48 h, gave superior results to liquid nitrogen, providing a more practical and cost-effective medium for getting samples to the lab.<sup>29</sup> Transportation in saline for up to 24 h was optimum<sup>29</sup> and Michel's medium is favoured for longer transportation times.<sup>28</sup>

## 8.0 Further investigations

The following additional investigations should be considered prior to commencing treatment: full blood count and differential, urea and electrolytes, liver function tests, fasting glucose and glycated haemoglobin (HbA1c), fasting lipids, antinuclear antibody (differential of pemphigus erythematosus), urinalysis, blood pressure, weight, height (children) and a pregnancy test in female patients at risk of pregnancy. Current guidelines on prevention of osteoporosis<sup>30</sup> should be followed, so a bone density scan early in the course of treatment may be needed. In anticipation of using an adjuvant immunosuppressant, appropriate recommended additional investigations and vaccinations should be undertaken. A baseline measure of disease activity (see section 9.1) and quality of life, supplemented by IIF and ELISA titres if facilities exist, will be useful for disease monitoring and judging treatment responses (see sections 9.0–9.2).

## 9.0 Disease monitoring

Decisions concerning ongoing disease management will be based on making an assessment of disease activity. The simplest way of monitoring disease activity is clinically, which can be done more objectively by using clinical disease scoring systems. Clinical disease activity assessment can be supplemented with immunological measures and quality-of-life scores.

### 9.1 Disease severity scoring

Numerous disease severity scoring systems exist, making it difficult to compare data between studies. Two validated severity scoring systems that have become frontrunners are the Pemphigus Disease Area Index (PDAI) and the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS),<sup>31–34</sup> each taking 2–5 min to complete.<sup>32,34</sup> These have also been validated for use in oral PV but are inferior to another system, the Oral

Disease Severity Score, which may be combined with ABSIS or PDAI in patients with skin or extraoral mucosal sites.<sup>35</sup>

It is recommended that disease severity is scored in routine clinical practice. It is essential in clinical trials.

## 9.2 Immunological monitoring

IIF can be used to express the quantity of pemphigus antibodies in serum as a series of discontinuous serum dilutions. It is subjective and operator dependent and the titre depends on the substrate used, due to variable amounts of antigen being expressed at different sites. In general, mucosal substrates are better for detection of desmoglein 3 antibodies, and skin better for detection of desmoglein 1 antibodies, with the use of both substrates enhancing sensitivity.<sup>36</sup> IIF titres can reflect disease activity, but the relationship is not perfect and examples of active disease with negative IIF or vice versa exist such that IIF cannot be relied upon for disease monitoring. Whether IIF using two substrates is more useful for disease monitoring is yet to be demonstrated.

Desmoglein 1 and 3 ELISAs are sensitive and specific assays providing an objective and quantitative measure of antibody levels. In general, ELISA levels are related to disease activity, with desmoglein 1 antibody levels associated with skin severity and desmoglein 3 levels associated with oral severity.<sup>37–41</sup> Titres usually fall with treatment and disease remission.<sup>40,42–45</sup> Patients followed over time also show fluctuations in ELISA levels that mirror disease activity<sup>37,41</sup> but, as with IIF, the relationship is not perfect: examples of patients with inactive disease and high ELISA titres and vice versa are reported,<sup>37,42–44</sup> and one study found that changes in desmoglein 3 antibody levels did not correlate with clinical activity.<sup>43</sup> Some of these problems reflect saturation of the ELISAs at higher values, which could be overcome by increasing the serum dilution.<sup>46</sup>

The use of sequential salivary antidesmoglein 3 IgG titres as a biomarker of disease activity is an emerging area of interest, and titres have recently been shown to reflect oral disease activity.<sup>26</sup>

In general, falling or persistently low and negative IIF or ELISA titres are a good sign, such that immunosuppression could be tapered. Rising or persistently high titres should be a cause for concern. Where facilities exist to follow titres, the information could be used as an adjunct to clinical assessment, but due to the imperfections of the assays discussed, good clinical judgement remains paramount.

## 10.0 Evaluating therapies in pemphigus vulgaris

In general, the quality of published data concerning the therapy of PV is poor. There are few good-quality randomized controlled trials (RCTs). The majority of data are confined to case reports and small case series in which cases of PV of variable severity may be included, often with other subtypes of pemphigus. Follow-up periods are often short, even in the larger trials, and dosing schedules vary widely. Trial design is

often poor, with different drug combinations used in different arms such that any differences in outcomes cannot be attributed to a single intervention. Controls are often indirect, involving comparisons of remission and mortality rates with historical controls, or comparison of maintenance corticosteroid doses before and after the addition of a given therapy. A huge number of outcome measures and disease definitions have also been used, making comparison between studies difficult. Finally, the rarity of PV means recruitment of sufficient numbers of patients is challenging; many studies are small and underpowered.

To address some of these issues, the International Pemphigus Committee has produced a consensus statement that outlines definitions of important time points and disease status.<sup>47</sup> In parallel, efforts are being made to use commonly accepted disease severity scores.<sup>32,33</sup> By using a commonly accepted set of core outcome measures, it is envisaged that trial data can be better compared and pooled such that small and underpowered individual studies could become of value as it would be possible to include them in larger meta-analyses. In addition, it is now widely acknowledged that the rarity of PV means cooperative research with multiple recruitment sites is needed to produce successful trials with adequate power.<sup>48</sup> It has been estimated that to demonstrate a 20% difference between interventions with 80% power, a study of more than 196 patients would be needed in PV.<sup>49</sup> Trials such as these, using a set of core outcome measures, are coming into being but at present, in most studies, it is difficult to judge the effect of individual drugs and make firm treatment recommendations. In these guidelines, we have listed the highest ranking level of evidence and given an overall recommendation for each therapy. A summary of treatment options is given in Table 4.

## 11.0 General principles of management

PV is an uncommon and potentially life-threatening disease requiring immunosuppressive treatment. It should be managed by secondary-care physicians experienced in the treatment of autoimmune mucocutaneous diseases. The management of active oral PV with systemic therapies should be approached in the same way as the management of active skin disease and could be managed by dermatologists where oral medicine expertise is not available.

The management of PV can be considered in two main phases: induction of remission and maintenance of remission.

### 11.1 Remission induction

In remission induction the initial aim of treatment is to induce disease control, defined as new lesions ceasing to form and established lesions beginning to heal.<sup>47</sup> Corticosteroids are the most effective and rapidly acting treatment for PV, hence they are critical in this phase. Using corticosteroids, disease control typically takes several weeks to achieve (median 3 weeks).<sup>50</sup> During this phase the intensity of treatment may need to be built up rapidly to suppress disease activity. Although adjuvant

drugs are often initiated during this phase, their immediate therapeutic benefit is relatively limited because of their slower onset. They are rarely used alone to induce remission in PV.

After disease control is achieved there follows a consolidation phase during which the drug doses used to induce disease control are continued. The end of this consolidation phase is defined arbitrarily as being reached when 80% of lesions have healed, both mucosal and skin, and there have been no new lesions for at least 2 weeks.<sup>47</sup> This phase may be relatively short, but could be considerably longer if there is extensive cutaneous ulceration. Healing of oral ulceration tends to take longer than that for skin, with the oral cavity often the last site to clear in those with mucocutaneous PV. The end of the consolidation phase is the point at which most clinicians would begin to taper treatment, usually the corticosteroid dose. Premature tapering of corticosteroids, before disease control is established and consolidated, is not recommended.

### 11.2 Remission maintenance

After induction there follows a maintenance phase during which treatment is gradually reduced (see section 11.3), in order to minimize side-effects, to the minimum required for disease control. The ultimate goal of treatment should be to maintain remission on prednisolone 10 mg daily or less, with 10 mg being the dose designated arbitrarily as 'minimal therapy' by international consensus.<sup>47</sup> PV is a chronic disease, and in one study 36% of patients required at least 10 years of treatment.<sup>51</sup>

Systemic corticosteroids are the most important element of remission induction and consolidation. In general, adjuvant drugs are slower in onset than corticosteroids. Their main role is in remission maintenance. Adjuvant drugs are combined commonly with corticosteroids with the aim of increasing efficacy and reducing maintenance corticosteroid doses and subsequent corticosteroid side-effects. Although mortality and complete remission rates have improved since the introduction of adjuvant drugs, this is in comparison with historical controls. Until 2017 there had been no prospective, high-quality controlled studies that demonstrated conclusively the presumed benefits of adjuvant drugs in PV.<sup>52</sup> Therefore, some authorities have not used adjuvant drugs unless there were contraindications or side-effects of corticosteroids, or if tapering the corticosteroids dose was associated with repeated relapses.<sup>9</sup> Some trials demonstrated lower cumulative corticosteroid doses, but without a difference in primary disease outcome measures, for azathioprine, cyclophosphamide and mycophenolate mofetil,<sup>53–55</sup> which we believe is a clinically relevant outcome. A systematic review and meta-analysis, which included 10 trials and pooled adjuncts together, concluded that they were not beneficial for achieving remission but collectively decreased risk of relapse by 29%.<sup>55</sup> Despite this sparsity of evidence, it was commonly believed that adjuvant drugs were likely to be beneficial, as proven in other areas of autoimmunity, and most centres use them as

standard practice. In 2017, the first RCT conclusively demonstrating the benefit of an adjuvant drug was published: rituximab combined with short-term prednisolone showed superior efficacy to prednisolone alone, with rates of complete remission of PV, off all treatment, of 89% compared with 28% at 2 years.<sup>45</sup>

An overview of PV management, with the aim of providing a brief reference for the clinical setting, is summarized in Table 1, and a more detailed description follows.

### 11.3 Treatment withdrawal

Withdrawal of treatment is a realistic aim, with one study reporting rates of complete remission off-therapy of 38%, 50% and 75% achieved in 3, 5 and 10 years from diagnosis, respectively.<sup>56</sup> Another study reported that 59% of patients were off treatment after a mean treatment duration of 3 years and this outcome was not associated with initial disease severity.<sup>57</sup> However, withdrawal of treatment should be cautious and not done prematurely; relapse rates are high initially, with 47% of successfully treated patients relapsing in one trial when treatment was stopped after 1 year.<sup>58</sup>

## 12.0 Oral corticosteroids (Strength of recommendation B, Level of evidence 1+; see Appendices)

Systemic corticosteroids are the best established therapy for the management of PV. Their introduction in the early 1950s resulted in a dramatic fall in mortality to an average of 30%,<sup>9</sup> with complete remission rates off-therapy of 13–20%.<sup>9,59</sup> Outcomes have continued to improve, and recent studies have shown that the rate of complete remission on low-dose corticosteroids (prednisolone 10 mg per day or less) is 52–76% at 1 year with very few deaths.<sup>53,54,60,61</sup>

Clinical improvement may be seen within days of starting corticosteroids and, on average, cessation of blistering takes 2–3 weeks<sup>50,53,61–64</sup> while full healing may take 3–8 weeks.<sup>50,61,65</sup> IIF titres fall with corticosteroid treatment but lag behind clinical improvement.<sup>66</sup>

The optimum corticosteroid dosing schedule is not known, and dosing schedules are largely empirical and based on practical experience. Early studies advocated high doses, for example initial doses of prednisolone 120–400 mg per day.<sup>62,65</sup> However, corticosteroid side-effects were common and dose

**Table 1** An overview of the management of pemphigus vulgaris

First-line therapy	<p>Corticosteroids</p> <ul style="list-style-type: none"> <li>• Oral prednisolone – optimal dose not established but suggest start with prednisolone 1 mg kg<sup>-1</sup> per day (or equivalent) in most cases, 0.5–1 mg kg<sup>-1</sup> in milder cases</li> <li>• Increase in 50–100% increments every 5–7 days if blistering continues</li> <li>• Consider pulsed intravenous corticosteroids if &gt; 1 mg kg<sup>-1</sup> oral prednisolone required, or as initial treatment in severe disease followed by 1 mg kg<sup>-1</sup> per day oral prednisolone</li> <li>• Taper dose once remission is induced and maintained, with absence of new blisters and healing of the majority of lesions (skin and mucosal). Aim to reduce to 10 mg daily or less</li> <li>• Assess risk of osteoporosis immediately</li> <li>• Effective in all stages of disease, including remission induction</li> </ul> <p>Combine corticosteroids with an adjuvant immunosuppressant</p> <ul style="list-style-type: none"> <li>• Azathioprine 2–3 mg kg<sup>-1</sup> per day (if TPMT normal)</li> <li>• Mycophenolate mofetil 2–3 g per day</li> <li>• Rituximab<sup>a</sup> (rheumatoid arthritis protocol, 2 × 1 g infusions, 2 weeks apart)</li> <li>• More important for remission maintenance than induction, due to delayed onset</li> </ul> <p>Good skin and oral care are essential</p>
Second-line therapy	<p>Consider switching to alternate corticosteroid-sparing agent if treatment failure with first-line adjuvant drug<sup>b</sup> (azathioprine, mycophenolate mofetil or rituximab) or mycophenolic acid 720–1080 mg twice daily if gastrointestinal symptoms from mycophenolate mofetil</p>
Third-line therapy	<p>Consider choice of additional treatment options based on assessment of individual patient need and consensus of multidisciplinary team. Options include</p> <ul style="list-style-type: none"> <li>• Cyclophosphamide</li> <li>• Immunosorption</li> <li>• Intravenous immunoglobulin</li> <li>• Methotrexate</li> <li>• Plasmapheresis or plasma exchange</li> </ul>

TPMT, thiopurine methyl transferase. <sup>a</sup>Rituximab is currently approved by National Health Service England as a third-line treatment for pemphigus. Regulatory authorities in many other countries have not yet approved rituximab as a first-line treatment. <sup>b</sup>Treatment failure is defined by international consensus<sup>47</sup> as continued disease activity or failure to heal despite 3 weeks of prednisolone 1.5 mg kg<sup>-1</sup> per day, or equivalent, or any of the following, given for 12 weeks: (i) azathioprine 2.5 mg kg<sup>-1</sup> per day (assuming normal TPMT), (ii) mycophenolate mofetil 1.5 g twice daily, (iii) cyclophosphamide 2 mg kg<sup>-1</sup> per day, (iv) methotrexate 20 mg per week.

related,<sup>67,68</sup> with one study estimating that up to 77% of deaths were corticosteroid related.<sup>67</sup> Therefore, a more moderate approach to corticosteroid therapy has been advocated. However, only one RCT has compared dosing schedules; initial therapy with low-dose prednisolone (30–60 mg per day) was compared with high-dose prednisolone (120–180 mg per day) in patients with severe pemphigus (19 with PV, three with PF) affecting > 50% of their body surface. There was no significant difference in the duration to achieve initial disease control or in relapse rates at 5 years, and there were no deaths.<sup>63</sup> However, it should be noted that the dose tapered more rapidly in the high-dose arm so that on average, by week 7 and thereafter, the daily corticosteroid dose was lower in the 'high-dose' arm. In contrast, a retrospective study showed benefit with higher corticosteroid doses: treatment with prednisolone 1.5 mg kg<sup>-1</sup> led to significantly shorter times to achieve initial disease control and remission compared with prednisolone 40 mg on alternate days combined with azathioprine, although there were fewer side-effects in the low-dose arm.<sup>60</sup>

It is common practice worldwide to initiate treatment at prednisolone 1–2 mg kg<sup>-1</sup> or equivalent,<sup>51,53,54,61,69–73</sup> with a majority of clinicians experienced in managing PV choosing 1 mg kg<sup>-1</sup>.<sup>69</sup> However, milder cases may be treated with more conservative corticosteroid doses such as 0.5–1 mg kg<sup>-1</sup>; tailored dosing according to disease severity is well established<sup>9,65</sup> and appropriate,<sup>74</sup> with no evidence to indicate that long-term outcomes are influenced by the intensity of initial treatment.<sup>57,74</sup>

If there is no response within 5–7 days, it is suggested that the dose should be increased in 50–100% increments until disease control is achieved, defined as no new lesions and the onset of healing in pre-existing ones.<sup>9,61,65,71,75</sup> If prednisolone doses above 1 mg kg<sup>-1</sup> per day are required, pulsed intravenous corticosteroids should be considered. Treatment failure for oral corticosteroids has been defined by international consensus as failure to achieve disease control despite 3 weeks of prednisolone 1.5 mg kg<sup>-1</sup> per day or equivalent.<sup>47</sup>

Once remission is induced and maintained with healing of the majority of lesions, both skin and oral, the dose of corticosteroids can be tapered cautiously. This includes assessing oral lesions, which are often the last to heal. The mouth and other mucosal sites must be examined in addition to the skin. Tapering before disease control is established and consolidated is not recommended. There is no established tapering schedule and those published in clinical trials vary widely,<sup>53,54,58,61,63,71,72,75–79</sup> with the dose by week 12 varying from 5 mg<sup>75</sup> to 60 mg daily.<sup>79</sup> The average tapering rate across these trials was 6 mg per week in the first 3 months.

A 50% reduction every 2 weeks has been suggested.<sup>9</sup> The GDG consensus is initially to reduce the daily dose by 5–10 mg of prednisolone every 2 weeks down to 20 mg daily, then by 2.5 mg every 2–4 weeks down to 10 mg daily and thereafter reduce slowly in increments of 1 mg. Prednisolone doses of 10 mg or less should be the aim of treatment, defined by international consensus as the minimal therapy in PV.<sup>47</sup>

Relapses in the short term can be managed by increasing the corticosteroid dose, although there is no consensus on the

optimum way to manage relapses. They are often milder than initial disease presentation and are managed typically with lower corticosteroid doses. Various approaches to managing relapses have been suggested, including reverting to the previous corticosteroid dose at which there was disease control;<sup>80</sup> doubling the corticosteroid dose,<sup>61,63,72</sup> with 50% incremental increases thereafter until disease control;<sup>61</sup> increasing to prednisolone 40 mg per day, or if already greater than this, to the previous dose at which disease control was achieved;<sup>71</sup> and increasing prednisolone dose by 10–20 mg per day.<sup>50,81</sup> Relapses that are more severe should be treated with corticosteroid doses as described for the initial presentation. At the time of relapse, in addition to increasing corticosteroid dose, long-term management should also be considered, as relapses may recur when the corticosteroid doses are tapered again. It may be appropriate to add an adjuvant drug, increase the dose of an existing adjuvant or switch to an alternative, if the current adjuvant drug has been given at a sufficient dose for at least 3 months (Table 1).

It is strongly recommended that guidelines for the prevention of corticosteroid-induced osteoporosis are followed.<sup>30,82</sup> A prednisolone dose of ≥ 7.5 mg for at least 3 months is considered a risk factor in those aged under 40 years, and any dose for those aged over 40 years.<sup>82</sup> Thus, all patients with PV are at risk, assuming they are likely to exceed these limits, and bone health should be considered immediately upon commencing treatment because the rate of bone loss is most marked in the first 6 months of treatment.<sup>83</sup>

## Summary

Systemic corticosteroids are a well-established and very effective treatment for PV. They should be used as first-line therapy.

## 13.0 Pulsed intravenous corticosteroids [Strength of recommendation D (GPP), Level of evidence 4]

Pulsed intravenous corticosteroids refers to the intermittent administration of high doses of corticosteroids, usually intravenous methylprednisolone (10–20 mg kg<sup>-1</sup> or 250–1000 mg) or equivalent doses of dexamethasone given on up to five consecutive days.<sup>84</sup> Generally, pulsed corticosteroids are given intravenously but they can be delivered orally.<sup>85</sup> The theoretical aims of 'pulsing' are to achieve more rapid and effective disease control compared with conventional oral dosing, thus allowing a reduction in long-term maintenance of corticosteroid doses and corticosteroid side-effects. These theoretical benefits have not been demonstrated conclusively.

In a well-designed, double-blind RCT, monthly oral dexamethasone pulses were of no additional benefit and were associated with more adverse effects compared with conventional oral corticosteroids and azathioprine.<sup>76</sup> However, this study was limited by small numbers (20 patients, 11 and nine in each arm) and a relatively short follow-up (1 year). One small, retrospective case-controlled study concluded that

pulsed intravenous methylprednisolone (one course of 250–1000 mg per day for 2–5 days in eight cases; two courses in one case) resulted in increased complete remission rates (44% vs. 0%) and lower mean maintenance oral corticosteroid doses in nine patients with recalcitrant PV compared with six controls.<sup>86</sup> In terms of the rapidity of disease control, a retrospective case series reported signs of improvement within a week of pulsed methylprednisolone in all 12 patients,<sup>87</sup> but similar responses have been reported with oral corticosteroids.

## Summary

There is no evidence that pulsed corticosteroids are superior to conventional oral corticosteroids for maintenance of most cases of PV. However, short-term pulsed corticosteroids could be considered in severe or recalcitrant PV to induce remission, particularly if there has been no response to high oral doses. There is no good evidence to support their use in this situation, but the personal experience of the GDG is that pulsing is very useful for rapid disease control in patients with severe disease.

## 14.0 Adjuvant drugs

### 14.1 Azathioprine (Strength of recommendation B, Level of evidence 1+)

#### 14.1.1 Introduction

Azathioprine is a commonly prescribed adjuvant drug in PV and was first used successfully in 1969 by Krakowski *et al.*<sup>88</sup> Numerous small case series have reported a corticosteroid-sparing effect.<sup>89–92</sup> The complete remission rates of 28–45% exceed those seen in historical controls treated with corticosteroids alone.<sup>9,59,91</sup> Mortality rates of 1.4–7% are lower than those seen in historical controls treated with corticosteroids alone.<sup>9,10,59,91</sup>

#### 14.1.2 Azathioprine as a single agent

In three cases, azathioprine was used successfully as a monotherapy to induce and maintain clinical remission with a fall in antibody titre.<sup>90,93</sup> However, there is a latent period of at least 6 weeks before the effects of azathioprine are seen,<sup>89–91,93</sup> and its use as a monotherapy to induce remission should therefore be reserved for mild cases only, if a delay in achieving disease control can be tolerated.

#### 14.1.3 Comparison with oral corticosteroids

The role of azathioprine as a corticosteroid-sparing drug has been demonstrated in a number of small studies. Chaide-menos *et al.* compared high-dose prednisolone (1.5 mg kg<sup>-1</sup> per day; n = 17) with low-dose prednisolone (40 mg on alternate days) plus azathioprine 100 mg per day (n = 19) in a retrospective comparison.<sup>60</sup> Both regimens were effective. Analysis of the 30 responders showed that the high-dose prednisolone group achieved a faster remission with greater side-effects. The

combination group had a significantly lower total prednisolone usage but a longer time until complete or partial remission. This was not an intention-to-treat analysis and the study was not powered adequately. In a retrospective study, described in section 14.4.2, the times to remission and complete remission off-treatment showed no significant differences when adding azathioprine (100 mg per day) to prednisolone (100 mg per day starting dose).<sup>94</sup>

In a large, unblinded RCT described in section 18.1, patients randomized to the prednisolone plus azathioprine arm (n = 30) had required lower cumulative corticosteroid doses at 1 year than those treated with prednisolone alone (n = 30), although efficacy was similar in these two arms.<sup>53</sup> In a subsequent study, the same authors performed a double-blind RCT comparing prednisolone (initial dose 2 mg kg<sup>-1</sup> per day; n = 28) plus placebo with prednisolone plus azathioprine (2.5 mg kg<sup>-1</sup> per day; n = 28) over 12 months.<sup>95</sup> Disease severity was measured using the Pemphigus Vulgaris Disease Activity Index (PVDAI) and included an intention-to-treat analysis. No significant differences were seen in the mean PVDAI scores or the corticosteroid doses between the two groups over the 12 months. However, subgroup analyses revealed differences in the two arms towards the end of the trial: in the final 3 months there were significant differences in the PVDAI and mean daily and cumulative prednisolone doses, favouring prednisolone plus azathioprine. The mean PVDAI of the prednisolone-only group was 2.41 and for prednisolone plus azathioprine it was 0.47 (P = 0.045, intention to treat).

#### 14.1.4 Comparison with other adjuvant drugs

Trials comparing azathioprine with mycophenolate mofetil and cyclophosphamide are described in section 18. In summary, two trials have compared azathioprine with mycophenolate mofetil<sup>53,71</sup> and there is evidence to suggest that azathioprine has a superior corticosteroid-sparing effect.<sup>52</sup> There is also some evidence that azathioprine may be less effective at achieving disease control.<sup>52,71</sup> One retrospective study suggested that azathioprine might be less effective than oral cyclophosphamide.<sup>94</sup> Three trials have compared azathioprine with pulsed cyclophosphamide regimens: one RCT showed no significant differences;<sup>70</sup> a non-randomized trial favoured pulsed cyclophosphamide, which showed a lower cumulative corticosteroid dose although efficacy was similar;<sup>72</sup> and a single-centre RCT showed lower cumulative corticosteroid doses in the azathioprine arm compared with the pulsed cyclophosphamide arm, which did not reach significance in the authors' analysis<sup>53</sup> but was considered significant in an independent Cochrane review.<sup>52</sup>

## Summary

Azathioprine is a well-established choice of adjuvant drug for the management of pemphigus. A reasonable duration of treatment is needed to test efficacy, and treatment failure should only be determined after at least 3 months at a dose of 2.5 mg kg<sup>-1</sup> in patients with normal thiopurine methyltransferase

levels.<sup>47</sup> Although there remains a lack of high-quality prospective randomized trials there is some evidence to suggest that the coadministration of azathioprine reduces the cumulative corticosteroid dose and has a superior corticosteroid-sparing effect compared with mycophenolate mofetil.

## 14.2 Mycophenolate mofetil (Strength of recommendation B, Level of evidence 1+)

### 14.2.1 Introduction

Mycophenolate mofetil is often used as a first-line adjuvant to corticosteroid agents. Total daily doses of 2–3 g are given typically in two divided doses with prednisolone, thus 1–1.5 g twice daily. In patients who experience gastrointestinal side-effects, mycophenolic acid can be given as an alternative, with the approximate equivalent dose being 720–1080 mg twice daily.

Several small, unblinded trials have suggested that mycophenolate mofetil is beneficial in pemphigus treatment. In a series of 12 patients who had relapsed on corticosteroids plus azathioprine, 11 improved on mycophenolate mofetil (2 g per day) and prednisolone (2 mg kg<sup>-1</sup>), allowing a reduction in the prednisolone dose to 5 mg per day or less during the follow-up of 1 year. The patients responded rapidly, with a fall in IIF titres, and were free of lesions within 8 weeks of initiating mycophenolate mofetil.<sup>96</sup> However, based on nine patients, Nousari *et al.* commented that higher doses of mycophenolate mofetil (2.5–3 g per day) were often required to induce remission in PV, and at least 8 weeks of treatment was necessary before clinical and immunological improvement was observed.<sup>97</sup> There have been more than 30 case series since these. Examples of the number of patients achieving disease control in previously refractory patients with PV then treated with mycophenolate mofetil as a corticosteroid-sparing agent include 71% (22 of 31),<sup>98</sup> 73% (eight of 11)<sup>99</sup> and 78% (14 of 18).<sup>100</sup> Few adverse effects were reported.

### 14.2.2 Comparison with oral corticosteroids

In the study described in section 18.1, 30 patients with PV were given prednisolone alone (initial dose 2 mg kg<sup>-1</sup>) and in another 30 it was combined with mycophenolate mofetil (1 g twice daily) in this single-centre unblinded RCT.<sup>53</sup> There were no significant differences in efficacy in these two arms. The cumulative corticosteroid dose in the mycophenolate mofetil arm was lower but did not reach statistical significance.<sup>52</sup>

In an unblinded RCT,<sup>61</sup> 47 patients (36 PV, 11 PF) were allocated randomly to receive methylprednisolone alone or methylprednisolone (initially 1 mg kg<sup>-1</sup> prednisolone equivalent) and mycophenolate mofetil (1.5 g twice daily). Disease activity was scored according to the number of lesions present. The authors reported no difference in the time to achieve disease control, induction of partial and complete remissions on or off minimal therapy, or the total amount of corticosteroids administered. There was no difference in the frequency of relapses or the development of side-effects and complications.<sup>61</sup>

There has been one double-blinded, placebo-controlled RCT.<sup>54</sup> In this multicentre study, 94 of 96 randomized patients were treated and 75 completed the study. Patients were allocated to either prednisone 1–2 mg per day (initial dose) plus placebo (n = 37), prednisone plus mycophenolate mofetil 2 g per day (n = 22) or prednisone plus mycophenolate mofetil 3 g per day (n = 37). The primary outcome measure was the proportion of patients in each arm responding to treatment as determined by an absence of new or persistent lesions and a prednisone dose of ≤ 10 mg daily dose from weeks 48–52. While the authors found no significant difference in the primary end points, the time to initial response was faster and the time to a sustained response was 12 weeks shorter in both mycophenolate mofetil-treated arms. In addition, the cumulative corticosteroid dose taken over weeks 12–52 of the study was significantly lower in the combined mycophenolate mofetil arm compared with the placebo arm (P = 0.028). Efficacy was similar in both mycophenolate mofetil arms, but infectious adverse events were higher in those taking 3 g daily. In both these arms infections were more common than in the placebo arm.<sup>54</sup>

### 14.2.3 Comparison with other adjuvant drugs

Studies comparing mycophenolate mofetil with azathioprine and cyclophosphamide are described in section 18. In summary, there is evidence that mycophenolate mofetil has an inferior corticosteroid-sparing effect compared with azathioprine<sup>52,53,71</sup> but may be more effective at achieving disease control.<sup>52,71</sup> Adverse events were not significantly different in these two studies but one did show fewer grade 3 and 4 adverse events with mycophenolate mofetil.<sup>71</sup> Mycophenolate mofetil has an inferior corticosteroid-sparing effect compared with pulsed cyclophosphamide.<sup>52</sup>

## Summary

On the basis of current knowledge, there is evidence that mycophenolate mofetil has a corticosteroid-sparing effect. It could be considered as an alternative to azathioprine in patients unresponsive to treatment or where comorbidities or baseline investigations preclude azathioprine. It has a more favourable side-effect profile than azathioprine and is well tolerated. Treatment failure has been defined by international consensus as failure to respond to 3 g daily for 3 months.<sup>47</sup>

## 14.3 Rituximab (Strength of recommendation B, Level of evidence 1+)

### 14.3.1 Introduction

Rituximab is a chimeric murine–human monoclonal antibody of the IgG1 subclass, directed against the B-lymphocyte-specific antigen CD20,<sup>101</sup> expressed by early B cells in the bone marrow, autoantigen-specific B cells, memory B cells and mature B cells. Following treatment with rituximab there is rapid and sustained depletion of circulating and tissue-based B

cells that is maintained for at least 6–12 months. Recent data suggest that rituximab may also affect T-cell function and modulate autoreactive T cells and production of T-cell cytokines.<sup>102</sup> Further details are provided in Appendix S2 (see Supporting Information).

#### 14.3.2 Efficacy

In an unblinded RCT, 90 newly diagnosed and treatment-naïve patients with moderate and severe PV ( $n = 74$ ) and PF ( $n = 16$ ) were treated with rituximab (1 g on days 0 and 14 and 0.5 g at 12 and 18 months) in combination with short-term prednisolone (0.5–1 mg kg<sup>-1</sup> for 3–6 months) compared with prednisolone alone (1–1.5 mg kg<sup>-1</sup> for 12–18 months).<sup>45</sup> There was a significant difference in primary outcome: 89% of patients in the rituximab arm were in complete remission off all treatment at 2 years compared with 34% of patients treated with prednisolone alone ( $P < 0.001$ ). The rates were 89% vs. 28% in those with PV ( $P < 0.001$ ). There were fewer severe adverse events in the rituximab-treated patients, which probably reflects the fact that prednisolone doses were higher and more prolonged in those treated with prednisolone alone. The lack of blinding is a flaw of this trial, and in particular the risk of withdrawal bias as dropout rates were higher in the prednisolone-only arm. However, reanalysis assuming that all withdrawals in the prednisolone-only arm went on to achieve remission off treatment still leads to a highly significant result. Nevertheless, the guideline group felt it appropriate to downgrade the recommendation rating to B based on this single unblinded RCT.

Previous studies of rituximab have considered its use in patients resistant to other therapies: multiple case series (reviewed in Ahmed and Shetty<sup>103</sup> and Wang *et al.*)<sup>104</sup> suggest that it is of utility in the treatment of PV, PF and paraneoplastic pemphigus, with rates of remission in refractory disease of up to 86% following a single cycle of treatment.<sup>105</sup> In a meta-analysis of 578 patients with pemphigus (496 PV), remission was achieved in 76% of patients following a single cycle of rituximab, and 39% were able to come off adjuvant treatments.<sup>104</sup> In this study the mean times to disease control and remission were 1.1 and 5.8 months, respectively. Relapse occurred in 40% of patients after an average duration of 14.5 months. Similar data are reported in an analysis of 451 patients with PV from case series: remission was achieved in 74–87% after a single cycle (16–58% remained on other therapies, 27–58% off adjuvant treatments).<sup>103</sup> They reported clinical responses within 6 weeks and a relapse rate of up to 65% occurring 13–17 months after rituximab.

In a single case, rituximab was used as a sole agent, and complete healing had been achieved 6 weeks after starting treatment.<sup>106</sup>

#### 14.3.3 Dose

Initial studies employed a dosing regimen derived from the treatment of patients with lymphoma, using four, weekly

infusions of 375 mg m<sup>-2</sup>.<sup>105</sup> A comparison of repeated weekly treatments of 375 mg m<sup>-2</sup> suggested that patients with pemphigus who received three or more infusions demonstrated more rapid complete remission of disease compared with those who received only one or two infusions (149 vs. 443 days) and lower levels of relapse (0% vs. 67%).<sup>107</sup>

More recently, an alternative regimen has been introduced, based on that employed in the treatment of rheumatoid arthritis (RA). A regimen of two infusions of rituximab 1 g, 2 weeks apart, has now been shown to be effective in retrospective<sup>108,109</sup> and prospective<sup>45,110</sup> studies. Modified protocols have been used, but data suggest that the 'low-dose' RA protocol (2 × 0.5-g infusions) has a lower response rate and shorter time to relapse than the standard RA protocol.<sup>111</sup>

Comparisons of the standard RA and lymphoma protocols have failed to show consistent superiority of either one. Two studies reported no significant differences,<sup>104,111</sup> although there was a trend to better outcomes in the lymphoma-protocol-treated patients in the study by Wang *et al.*<sup>104</sup> In their analysis, Ahmed and Shetty showed significantly better clinical responses in the RA-protocol-treated patients but with higher relapse rates (nonsignificant).<sup>103</sup> Regarding cost, the RA protocol is less expensive, in terms of both drug cost and the associated expense of requiring two rather than four intravenous infusions. Lower-dose treatment (two infusions of 500mg each, two weeks apart) has been studied and reported to be effective,<sup>112,113</sup> although this approach may be associated with poorer response and increased rates of relapse.<sup>111,114</sup> Lower-dose rituximab (500 mg) has been used to control relapse following successful treatment with a standard 2 × 1 g induction regimen.<sup>115</sup>

In a single report of resistant oral pemphigus rituximab was used intralesionally.<sup>116</sup>

#### 14.3.4 Combination with other therapies

In general, rituximab has been used as part of combination therapy including systemic corticosteroids together with cytotoxic immunosuppression, or as an adjunct to treatment with intravenous immunoglobulin (IVIg)<sup>117</sup> or immunoabsorption.<sup>118–120</sup> Of 372 patients with PV who received rituximab reported in the study by Ahmed and Shetty, 79–97% were treated concomitantly with adjuvant corticosteroids and/or immunosuppressants (59–69% with both).<sup>103</sup> Two studies have employed rituximab together with prednisolone alone, and in one study of 42 patients to good effect.<sup>121</sup> The other, an RCT with 46 newly diagnosed patients (38 PV), resulted in complete remission off treatment in 89% of patients.<sup>45</sup> At present, there are insufficient comparative data to indicate which of these approaches is preferable, from the perspective of either efficacy or adverse effects.

Adjuvant systemic immunosuppressive drugs can be continued with concomitant use of rituximab, but dose reduction should be considered to decrease the risk of infections and other adverse effects related to immunosuppression.

### 14.3.5 Novel anti-CD20 agents

A number of novel anti-B-cell antibodies are currently in development,<sup>122</sup> although to date only one has been reported to have been used in a patient with pemphigus. Veltuzumab (a humanized anti-CD20 antibody) was used as two subcutaneous injections 2 weeks apart in a patient with severe pemphigus that was refractory to conventional immunosuppression and several cycles of rituximab.<sup>123</sup> Complete remission resulted and was sustained for 2 years, at which point the patient was re-treated, again with induction of remission. While rituximab resistance is rare, such novel agents will undoubtedly be of benefit in some patients and may also be more convenient as a result of the subcutaneous route of administration.

### Summary

The superior efficacy of rituximab and short-term corticosteroids compared with corticosteroids alone has been demonstrated in a single unblinded RCT of newly diagnosed patients with pemphigus. There is also evidence that rituximab is effective in treatment-resistant disease, and in most of these cases it has been given in combination with standard immunosuppression. Rituximab is effective for all forms of pemphigus. The 2 × 1 g RA dosing protocol is preferred due to cost considerations, with similar efficacy to the lymphoma protocol.

## 14.4 Cyclophosphamide

### 14.4.1 Introduction

Cyclophosphamide treatment regimens in PV vary from daily oral administration to fortnightly or monthly pulses, or a combination of these.<sup>124</sup> Large, comparative trials examining differing doses and regimens are lacking in PV. However, it is interesting to note that studies analysing pulsed intravenous and daily oral cyclophosphamide therapies in the treatment of vasculitis suggest equal efficacy, but with a lower cumulative dose and rate of complications for pulsed treatment,<sup>125,126</sup> although the risk of relapse may be higher.<sup>126,127</sup> Guidelines produced for the treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis also recommend discontinuation of cyclophosphamide, both oral and intravenous, after 3–6 months, with transfer to an alternative maintenance therapy, azathioprine or methotrexate, because of the risk of haemorrhagic cystitis, cancer and infertility associated with prolonged exposure to cyclophosphamide. The recommended total duration of cyclophosphamide treatment in this context is up to a maximum of 6 months.<sup>128</sup>

### 14.4.2 Oral cyclophosphamide (Strength of recommendation D, Level of evidence 3)

Early studies reported the corticosteroid-sparing effects of cyclophosphamide at doses of 50–200 mg per day in case series of up to six patients.<sup>129–133</sup> Prolonged remission with

cessation of all therapy was observed in some cases.<sup>130</sup> In a retrospective case series including 20 patients with PV who had failed or were intolerant to azathioprine or mycophenolate mofetil, or had severe PV, cyclophosphamide 2–2.5 mg kg<sup>-1</sup> with prednisolone, initially at 1 mg kg<sup>-1</sup> per day, led to remission on minimal prednisolone doses (< 12.5 mg per day) in 85% of patients.<sup>134</sup> A larger retrospective study included 51 patients treated with cyclophosphamide 100 mg daily (1.1–1.5 mg kg<sup>-1</sup>) and prednisolone 100 mg daily (1.1–1.5 mg kg<sup>-1</sup>) compared with prednisolone alone (n = 20) or combined with azathioprine (n = 16) or ciclosporin (n = 14). The time to clinical and immunological remission was significantly shorter in the cyclophosphamide arm, with lower cumulative corticosteroid doses, suggesting that cyclophosphamide is more effective than prednisolone alone and is superior to azathioprine and ciclosporin.<sup>94</sup> However, in an earlier study superiority was not demonstrated: the efficacy of prednisolone (40 mg per day) alone was compared with prednisolone/cyclophosphamide (100 mg) and prednisolone/ciclosporin (5 mg kg<sup>-1</sup>) in 28 patients with oral pemphigus.<sup>27</sup> There was no significant difference in the duration to achieve remission or in relapse rates between the three groups, but cyclophosphamide and ciclosporin were given for a brief period of only 2–3 months.<sup>27</sup> Treatment failure for oral cyclophosphamide has been defined by international consensus as failure to achieve disease control after 3 months of treatment at 2 mg kg<sup>-1</sup> per day.<sup>47</sup>

### Summary

Oral cyclophosphamide 1–2 mg kg<sup>-1</sup> could be considered as an alternative to azathioprine or mycophenolate mofetil. Due to concerns about its toxicity, it is best reserved for patients with recalcitrant or severe PV.

### 14.4.3 Intravenous cyclophosphamide (Strength of recommendation B, Level of evidence 2+)

**Pulsed intravenous cyclophosphamide with dexamethasone or methylprednisolone** This refers to the intermittent administration of high doses of intravenous corticosteroids and cyclophosphamide, usually three daily doses of dexamethasone (100 mg) or methylprednisolone (500–1000 mg) and a single dose of cyclophosphamide (500 mg) given monthly. Doses and frequency are arbitrary.

Dexamethasone–cyclophosphamide pulse (DCP) therapy for PV, first described in 1984 by Pasricha and Ramji,<sup>135</sup> is widely used in India for all types of pemphigus. The originally described regimen comprises four phases. Phase 1 consists of monthly intravenous dexamethasone 100 mg on three consecutive days with 500 mg intravenous cyclophosphamide on day 2. Low-dose daily oral cyclophosphamide (50 mg) is administered between pulses. Pulsing is continued until clinical remission and followed by a consolidation phase of a further six DCP courses (phase 2). Oral cyclophosphamide is then continued alone (phase 3) and if there are no relapses after 1 year,

all treatment is withdrawn (phase 4). Minor modifications have been made to the regimen, including extending phase 2 to 9 months, reducing phase 3 to 9 months and the addition of daily oral corticosteroids if needed during phase 1.<sup>136</sup> Using the original regimen, 81% (346 of 425) of patients with pemphigus were in remission and had been off all therapy for at least 2 years, with 74% (313 of 425) for more than 5 years.<sup>136</sup> Four percent of patients died during treatment. Using the modified regimen, 86% (106 of 123) of patients with pemphigus had completed treatment and had been off therapy for at least 2 years, with 50% (62 of 123) for more than 5 years. The mortality rate was 2%.

Many other retrospective case series describing the encouraging results of this treatment approach have been published both from Indian centres<sup>137–143</sup> and from other countries around the world including Iran, South Africa, the U.K. and Serbia.<sup>144–147</sup> In one study, 100% of 32 patients with PV completed the regimen and were off treatment, in remission.<sup>138</sup>

Advocates of the DCP regimen claim relative freedom from corticosteroid side-effects, but 20–85% of menstruating women developed amenorrhoea;<sup>145,147–149</sup> azoospermia in men was also noted. Haemorrhagic cystitis occurred in 0.6%<sup>149</sup> and pituitary–adrenal suppression in 55% (17 of 31) of patients.<sup>150</sup>

**Dexamethasone–cyclophosphamide pulse regimen compared with oral corticosteroids** DCP therapy has not been tested rigorously against other treatment protocols in controlled trials, but one study has compared the 6% mortality achieved in 50 patients (45 PV) on DCP therapy with an estimated 25–30% mortality in historical cohorts on conventional corticosteroid therapy at the same institute.<sup>137</sup> More recent studies also indicate an advantage of combining pulsed cyclophosphamide with conventional corticosteroids compared with corticosteroids alone; neither used DCP therapy. In a controlled, open-label study, described in section 18.1, the addition of intravenous pulsed cyclophosphamide 1 g monthly for 6 months, then every 2 months, to conventional oral prednisolone resulted in significantly lower cumulative corticosteroid dose at 1 year.<sup>53</sup> Similarly, in a randomized, prospective unblinded trial, 60 patients with PV were randomized to receive prednisolone 1 mg kg<sup>-1</sup> per day with or without monthly intravenous cyclophosphamide 15 mg kg<sup>-1</sup> for 1 year. There were no significant differences in the two treatment arms, but many outcomes tended to be better in the arm that included pulsed cyclophosphamide, with reduced relapse rates and cumulative corticosteroid doses.<sup>58</sup>

**Dexamethasone–cyclophosphamide pulse regimen compared with alternative pulsing protocols** One study has compared DCP therapy with an alternative pulsing protocol: in a prospective, randomized open-label trial, 28 patients with PV received either DCP therapy or conventional oral prednisolone 1.5 mg kg<sup>-1</sup> plus monthly cyclophosphamide pulses 15 mg kg<sup>-1</sup>. Most efficacy parameters were similar, although the time to achieve remission was significantly shorter in the oral prednisolone plus

cyclophosphamide 15 mg kg<sup>-1</sup> arm.<sup>79</sup> However, the period of study was 1 year only.

**Comparison of pulsed cyclophosphamide with other adjuvant drugs** Modified DCP regimens used in several trials have failed to demonstrate consistent superiority over other corticosteroid/adjuvant PV treatment regimens. Studies comparing pulsed cyclophosphamide with azathioprine and mycophenolate mofetil are summarized in section 18. In summary, three trials have compared azathioprine with pulsed cyclophosphamide regimens: one RCT showed no significant differences;<sup>70</sup> a nonrandomized trial favoured pulsed cyclophosphamide, which showed a lower cumulative corticosteroid dose although efficacy was similar;<sup>72</sup> and a single-centre RCT showed lower cumulative corticosteroid doses in the azathioprine arm, which did not reach significance in the authors' analysis but was considered significant in an independent Cochrane review.<sup>52</sup> Pulsed cyclophosphamide has a superior corticosteroid-sparing effect compared with mycophenolate mofetil.<sup>52,53</sup>

**Dose** The dose of intravenous cyclophosphamide most commonly reported for the treatment of PV is a fixed dose of 500 mg monthly, but this is arbitrary and is often combined with 50 mg per day oral cyclophosphamide. Three studies have given intravenous cyclophosphamide 15 mg kg<sup>-1</sup> monthly combined with conventional oral corticosteroids and without daily oral cyclophosphamide.<sup>58,79,81</sup> In another study, a fixed dose of intravenous cyclophosphamide 1 g monthly was given, without daily oral cyclophosphamide, and combined with conventional oral corticosteroids.<sup>53</sup> It is common practice to combine intravenous cyclophosphamide with mesna to reduce the risk of haemorrhagic cystitis.<sup>124</sup>

The dose of 15 mg kg<sup>-1</sup> for an intravenous cyclophosphamide pulse is commonly used in the treatment of other severe autoimmune diseases. For example, in remission induction of ANCA-associated systemic vasculitis, pulsed intravenous cyclophosphamide 15 mg kg<sup>-1</sup> (maximum dose 1500 mg) is given initially every 2 weeks, reducing to every 3 weeks and continued for a maximum of 6 months.<sup>128</sup>

## Summary

There is some evidence that pulsed cyclophosphamide therapy may reduce cumulative corticosteroid dose. There is no consistent evidence that it is more effective than other adjuvant drugs, so in view of concerns about long-term toxicity and the practical disadvantages of administering regular intravenous treatment, it is best reserved for severe or recalcitrant cases of PV.

### 14.5 Intravenous immunoglobulin (Strength of recommendation B, Level of evidence 2++)

Many reports have suggested the utility of IVIg in patients with PV,<sup>151–154</sup> and a recent double-blind, placebo-controlled study in 61 patients has confirmed this in a robust way.<sup>155</sup> Patients

with PV treated with a single cycle of IVIg (either 1 g kg<sup>-1</sup> or 2 g kg<sup>-1</sup> divided over 5 days) did significantly better, measured according to the need for additional treatment, than those treated with placebo, and a dose–response effect was demonstrated. Clinical improvement was measured objectively and seen by day 8 in the higher-dose treatment arm. In addition, a significant fall in desmoglein antibody titres was demonstrated in both treatment groups with no fall in the placebo group. A placebo-controlled crossover trial of IVIg in a single patient also confirmed its efficacy, with significantly improved disease activity scores and lower indirect immunofluorescence titres and desmoglein 1 and 3 antibody levels.<sup>156</sup>

In pemphigus, IVIg is generally used at high dose, typically 2 g kg<sup>-1</sup> in divided doses over several days, together with corticosteroids with or without cytotoxic immunosuppressive agents such as azathioprine or mycophenolate mofetil. Treatment is given at monthly intervals and may need to be prolonged for continued effect. Thus, multiple treatments will be needed if used to maintain remission. IVIg seems to act by increasing catabolism of pathogenic antibodies.<sup>157,158</sup> It is generally well tolerated<sup>154</sup> and has the attraction over other adjuvant therapies that it does not increase the risk of infection. IVIg has been used to treat pemphigus in pregnancy<sup>159</sup> and in children.<sup>160</sup>

While uncommon, adverse effects of IVIg do occur, including headache, aseptic meningitis and anaphylaxis, which is a particular risk in patients who are IgA deficient.

## Summary

IVIg could be considered as maintenance treatment in patients with refractory disease unresponsive to other adjuvant drugs. In view of reports of a rapid action in some cases, it may also be used to help induce remission in patients with severe PV while slower-acting drugs take effect. IVIg should be considered as part of the acute management of severe or widespread pemphigus and in patients who are at particularly high risk of infection.

### 14.6 Methotrexate (Strength of recommendation D, Level of evidence 3)

Methotrexate has been used as an immunomodulatory and corticosteroid-sparing agent in a variety of skin diseases. Studies from the late 1960s and early 1970s<sup>14,161–163</sup> attributed high morbidity and mortality to methotrexate and hence it fell out of favour for its adjuvant use in PV. Three of four patients cited in one report died, but high doses of methotrexate had been used (125–420 mg per week) in combination with prednisolone 40–240 mg per day.<sup>14</sup> There have been no controlled trials evaluating the role of methotrexate in the treatment of PV.<sup>162–166</sup>

A retrospective review of 116 patients with PV revealed clinical improvement in 83% (96 of 116) when methotrexate was used in doses of 10–50 mg per week, in combination with corticosteroids. Thirteen patients did not improve, two

had it discontinued for unknown reasons, and five died from causes unrelated to methotrexate therapy. Of the responders, 14 patients were clear at a mean of 2.6 years (range 3 months to 18 years) after discontinuation of all systemic therapy.<sup>167</sup>

Two retrospective studies have shown a corticosteroid-sparing effect with the use of methotrexate in PV. In a 25-year survey of 53 patients treated with methotrexate and systemic corticosteroids, there was a 50% reduction in the dose of corticosteroids,<sup>168</sup> and in the second study, prednisolone (mean dose prior to treatment with methotrexate 20 mg per day, range 3–40) was discontinued in six of nine patients.<sup>169</sup>

In 2012, a retrospective review of methotrexate use in PV reported its effectiveness in moderate-to-severe cases as an adjuvant to systemic corticosteroids. A predetermined severity score was used by the authors, which included the number of erosions, percentage of body surface involved and the dose of prednisolone used. In total 30 patients were identified and used methotrexate 15 mg per week. Of the 25 patients described as having severe or moderate disease in the study, 84% (21 of 25) improved their severity score within 6 months ( $P < 0.001$ ). Only 13% (four of 30) experienced side-effects. The dose of prednisolone was reduced (range 2.5–85 mg) in 23 patients (77%), and in 21 patients (70%) the decrease was 50% or more.<sup>170</sup>

A retrospective review by Tran *et al.*<sup>171</sup> on the adjunctive use of methotrexate in patients with PV has demonstrated its effectiveness as a corticosteroid-sparing agent; 23 patients with PV were treated with methotrexate, of whom 21 (91%) experienced improvement (as measured by reduction in the prednisolone dose). Sixteen patients (70%) were eventually weaned off prednisolone completely. The mean dose of methotrexate used in this study was 18.9 mg per week (range 15–25).

## Summary

Given the limitations of the data available, it would be difficult to recommend methotrexate as a first-line agent in the treatment of PV.<sup>172</sup> Methotrexate could be considered as an adjuvant drug if more established drugs cannot be used or have failed. International consensus has defined treatment failure as persistent disease despite methotrexate 20 mg per week for at least 12 weeks.<sup>47</sup>

### 14.7 Dapsone (Level of evidence 1–)

Dapsone has been reported to be beneficial as an adjuvant drug in several case reports of PV.<sup>173–177</sup> However, in three of these cases, it was started either with or shortly after prednisolone, and in two cases it was started after long-standing prednisolone was increased to high doses. Therefore, it is difficult to be certain whether dapsone had a significant role if any.

In a case series, five of nine patients with PV in the maintenance phase of treatment and who had been unable to reduce their prednisone dose below 15 mg per day experienced a

mean  $\pm$  SEM drop of  $67 \pm 7.1\%$  in prednisone dose after 4 months of maximal dapsone treatment and an  $84\% \pm 3.5\%$  drop in prednisone dose after 8 months of dapsone treatment.<sup>178</sup>

There has been one double-blind, placebo-controlled RCT undertaken to look for a potential corticosteroid-sparing effect of dapsone. Nineteen patients with PV on maintenance treatment with corticosteroids and/or immunosuppression were randomized to additional dapsone ( $n = 9$ ) vs. placebo ( $n = 10$ ). The primary outcome measure was reduction of prednisolone to  $7.5$  mg daily for at least 30 days within 1 year of achieving the maximum dapsone dose (150–200 mg per day). The results were based on an intention-to-treat analysis and did not show a statistical difference: 56% (five of nine) of the dapsone group were treated successfully, three failed treatment and one left the study. Among the placebo group 30% (three of 10) were treated successfully, 57% (four of seven) of those who failed treatment were treated with dapsone and in 75% (three of four) of those it was successful. Among those who completed the dapsone trial, 73% (eight of 11) vs. 30% (three of 10) on placebo showed a corticosteroid-sparing effect with dapsone. However, the study numbers are very small and at best may show only a slight trend for a corticosteroid-sparing effect with dapsone.<sup>77</sup>

### Summary

There is weak evidence to suggest that dapsone may have a corticosteroid-sparing effect. Larger placebo-controlled RCTs are needed.

### 14.8 Tetracyclines/nicotinamide (Level of evidence 3)

Tetracyclines have been used in the treatment of PV, with or without nicotinamide, in varying combinations. Sixteen patients were given nicotinamide 1.5 g and tetracycline 2 g daily. In 12, no systemic corticosteroids were given, and of these, three cleared and three improved.<sup>179,180</sup> Of the four patients given additional prednisolone, there was clearance in one, partial improvement in two and no response in another.<sup>179</sup>

Thirteen hospitalized patients with PV were given tetracycline 2 g daily for a month followed by 1 g per day for the next 4 weeks in combination with oral prednisolone. They had a faster response rate and required lower doses of prednisolone compared with seven historical corticosteroid-treated controls.<sup>181</sup>

Two studies using minocycline 50–200 mg per day as an adjuvant drug reported improvement and a corticosteroid-sparing effect in 54% of patients (seven of 13).<sup>182,183</sup>

### Summary

Tetracyclines, with or without nicotinamide, are not widely used for the treatment of PV, and evidence of their corticosteroid-sparing role is weak, but they could be considered as adjuvant treatment, perhaps in milder cases of PV.

### 14.9 Sulfasalazine and pentoxifylline (Level of evidence 2–)

A double-blind, placebo-controlled clinical trial in 64 patients with PV was carried out to ascertain the value of sulfasalazine and pentoxifylline as an adjuvant therapy for PV. Patients were not randomized. The drugs were chosen as low-cost, antitumour necrosis factor (anti-TNF) agents. All patients received standard pulsed therapy with intravenous corticosteroid (500 mg on five consecutive days) and pulsed cyclophosphamide (on day 1) in a 2- to 4-weekly cycle with oral cyclophosphamide (100 mg per day) and oral corticosteroid (60 mg per twice weekly) between the cycles. In addition, group 1 ( $n = 42$ ) were treated with oral sulfasalazine 500 mg twice daily and pentoxifylline 400 mg twice daily for 8 weeks, while group 2 ( $n = 22$ ) received a placebo. The serum level of TNF- $\alpha$  was higher statistically in both groups of patients than in the healthy individuals. There was a statistically significant decrease in the serum levels of TNF- $\alpha$  in patients in group 1 compared with those in group 2 at 6 and 8 weeks. There was also a rapid clinical improvement in patients in group 1 compared with those in group 2.<sup>184</sup>

### Summary

There is some evidence to support the use of pentoxifylline and sulfasalazine as adjuvant therapy in the treatment of PV, but further studies are required.

### 14.10 Chlorambucil (Level of evidence 3)

Like cyclophosphamide, chlorambucil is a nitrogen mustard alkylating agent. Since the last guidelines were compiled, there have been no new reports of the use of chlorambucil in PV. The biggest series, published in 2000, involved seven patients with PV who had failed to respond to other corticosteroids and immunosuppressants. They were given oral chlorambucil 4 mg per day, titrated upwards according to clinical response. There was improvement or remission in five patients and a corticosteroid-sparing effect was noted. A fall in IIF titres was reported in three of four cases.<sup>185</sup> The lack of bladder toxicity with chlorambucil is an advantage compared with cyclophosphamide.

### Summary

Chlorambucil could be considered as an adjuvant drug if more established options cannot be used, but there are limited data to support its use.

### 14.11 Gold (Strength of recommendation D, Level of evidence 3)

Gold is a historical treatment, rarely used now in the treatment of PV. Most studies have used intramuscular gold, given as sodium aurothiomalate, initially at a dose of 50 mg per week as an intramuscular injection if test doses were tolerated.

It was used successfully as monotherapy in five patients, with an associated fall in IIF titres.<sup>186,187</sup> However, it has been used more commonly as an adjuvant drug, and corticosteroid-sparing effects are reported.

Penneys *et al.* reported a series of patients receiving gold for up to 4 years, with 14 of 15 patients responding. Eight achieved remission off-treatment after a mean of 21 months, seven achieved remission on treatment and one stopped due to side-effects.<sup>188</sup> In a retrospective review of 26 patients treated with gold over 10 years, a response was seen in 62% and complete remission off-treatment had occurred in four patients. Toxicity was seen in 42%. The average dose of prednisolone was reduced from 55 mg per day before gold to 9 mg per day at the end of the study.<sup>189</sup> A more recent study used gold as an adjuvant therapy in 13 patients, with prednisolone doses ranging from 7.5 to 100 mg. The addition of 50 mg intramuscular gold was felt to be beneficial as seven patients went into complete remission and four were able to reduce prednisolone doses.<sup>190</sup>

Significantly, there are also case reports implicating gold as a trigger for pemphigus. Gold compounds contain a thiol group, which has previously been implicated in drug-induced pemphigus. Lo Schiavo *et al.* reported a convincing case of gold-induced pemphigus in a patient with rheumatoid arthritis, with complete resolution on withdrawal of gold.<sup>191</sup>

## Summary

Gold is now a historical treatment in most developed health-care systems. It could be considered as an alternative to more established adjuvant drugs if they cannot be used or are unavailable. However, the lack of randomized trial data makes the magnitude of an effect uncertain and there is a risk of gold acting as a disease trigger.

### 14.12 Ciclosporin (Level of evidence 1–)

There are a number of case reports suggesting that ciclosporin is a useful adjuvant with corticosteroid-sparing effects in PV.<sup>64,192–194</sup> However, a small prospective single-centre RCT of 33 patients comparing oral methylprednisolone 1 mg kg<sup>-1</sup> alone vs. methylprednisolone with ciclosporin 5 mg kg<sup>-1</sup> found no statistically significant difference in outcome measures such as time to healing, complete remission rate and cumulative corticosteroid dose. More side-effects were encountered in the ciclosporin group during a mean follow-up period of 5 years.<sup>195</sup> There were no deaths, and 10 patients (five from each group) were in complete remission, off all therapy, while the others were taking an average of prednisone 2.5 mg per day.<sup>195</sup> Olszewska *et al.* reported a retrospective series of 101 patients with PV treated with prednisolone alone (*n* = 20) or in combination with adjuvant immunosuppressants, including azathioprine (*n* = 16), ciclosporin (*n* = 14) and oral cyclophosphamide (*n* = 51).<sup>94</sup> Cyclophosphamide plus prednisolone was significantly better at inducing remission than prednisolone alone. Ciclosporin

did not add any significant benefit. The proportion remaining relapse free 5 years after discontinuation of treatment was lowest in the ciclosporin group, at 43%, and highest in the cyclophosphamide group at 69%.<sup>94</sup>

## Summary

On the basis of current evidence, ciclosporin cannot be recommended as an adjuvant drug in PV.

### 15.0 Plasma exchange/plasmapheresis (Strength of recommendation D, Level of evidence 3)

Plasma exchange has been used for many years in the management of antibody-mediated autoimmune disease, including pemphigus. Thus, multiple case reports and small case series have reported clinical benefit, short-term falls in IIF titres and a corticosteroid-sparing effect of plasma exchange.<sup>196–208</sup> In general, these were problematic patients with either corticosteroid side-effects, poorly controlled disease on conventional therapy or life-threatening disease. However, a randomized study of patients with newly diagnosed pemphigus treated with oral corticosteroids with or without additional plasma exchanges failed to demonstrate any additional clinical benefit of plasma exchange. Cumulative corticosteroid doses and changes in IIF titre in the two groups were similar. Furthermore, there were four deaths from sepsis in the plasma exchange group.<sup>209</sup>

In the cases reported that have been treated successfully, plasma exchange has been combined with both corticosteroids and immunosuppressive drugs – it is thought that the latter are necessary for sustained clinical effect in order to prevent rebound production of autoantibodies stimulated by the plasma exchange.<sup>196,199,204,205,210–213</sup> IVIg has been reported to have a similar action and has been used successfully in combination with plasmapheresis.<sup>214</sup>

Plasma exchange is not without adverse effects as, in addition to pathogenic immunoglobulins, other important plasma proteins are removed such as clotting factors that can result in coagulation defects on removal.<sup>215</sup>

## Summary

Plasma exchange cannot be recommended as a routine treatment option in newly presenting patients with pemphigus but may be considered in refractory cases if combined with corticosteroids and immunosuppressant drugs.

### 16.0 Extracorporeal photopheresis (Strength of recommendation D, Level of evidence 3)

Extracorporeal photopheresis is known to have immunomodulatory effects<sup>216</sup> and has been used in small numbers of patients with pemphigus;<sup>217–222</sup> there are no RCTs. In a recent case series, eight patients with pemphigus were treated with

two to six cycles of extracorporeal photopheresis, resulting in complete remission in all but one case. Steroid doses could be tapered in all treated patients.<sup>223</sup>

### Summary

Extracorporeal photopheresis could be considered in recalcitrant cases of PV where there has been failure to improve with more conventional therapy.

## 17.0 Immunoabsorption (Strength of recommendation D, Level of evidence 3)

Immunoabsorption is an extracorporeal apheresis technique in which patient serum is passed over a matrix that selectively adsorbs immunoglobulin. Consequently it removes circulating pathogenic antibodies and is widely used in transplantation medicine.<sup>224</sup> Immunoabsorption was first used in the management of pemphigus in 1999 and several case series and reports have evidenced its utility since then.<sup>225–227</sup> Various matrices have been used including staphylococcal protein A and tryptophan.<sup>226–228</sup>

Immunoabsorption has been used together with rituximab<sup>118,119</sup> and other adjuvant immunosuppressive agents.<sup>120,226,227</sup> It is effective in difficult-to-treat disease and represents a rational approach in the reduction of circulating pathogenic antibody levels when combined with treatment directed at suppressing new antibody formation such as rituximab.<sup>118</sup> Daily treatment over three consecutive days can result in falls in desmoglein antibody levels of up to 95%.<sup>228</sup> As yet, there is no consensus on an optimal matrix or regimen, and the use of immunoabsorption should be reserved for the treatment of patients resistant to or intolerant of other approaches.

### Summary

Immunoabsorption could be considered in recalcitrant cases of PV where there has been failure to improve with more conventional therapy.

## 18.0 Comparisons of systemic adjuvant drugs

### 18.1 Azathioprine and mycophenolate mofetil

In an unblinded multicentre RCT, 40 patients with pemphigus (33 PV and seven PF) were randomized to receive mycophenolate mofetil (1 g twice daily,  $n = 21$ ) or azathioprine (2 mg kg<sup>-1</sup> per day,  $n = 18$ ), both in combination with a standardized corticosteroid regimen (methylprednisolone, initial dose 2 mg kg<sup>-1</sup> per day); they were followed up for 2 years. There were no significant differences in efficacy, adverse event profile or cumulative corticosteroid dose between the two arms. There was a trend towards azathioprine achieving faster clinical remission, although more patients achieved remission with mycophenolate mofetil (95%, 20 of 21) after a mean of 91 days vs. azathioprine

(72%, 13 of 18) after a mean of 74 days, and there were fewer grade 3 or 4 adverse events with mycophenolate mofetil (19% vs. 33% for azathioprine). However, the study was small with wide confidence intervals.<sup>71</sup>

In a further unblinded single-centre RCT, mycophenolate mofetil and azathioprine were compared as adjuvant drugs, in addition to pulsed cyclophosphamide.<sup>53</sup> In total 120 patients with PV were randomized to four groups of 30 patients: prednisolone alone (initial dose 2 mg kg<sup>-1</sup> per day); prednisolone plus azathioprine (2.5 mg kg<sup>-1</sup> per day for 2 months followed by 50 mg daily); prednisolone plus mycophenolate mofetil (2 g per day); and prednisolone plus intravenous cyclophosphamide (1 g monthly for 6 months, then 1 g every 2 months). In total 111 patients completed the 1-year follow-up. Efficacy and adverse events were similar in all four arms, but the cumulative corticosteroid dose was significantly higher in the prednisolone-only arm compared with the combined adjuvant groups. The lowest cumulative dose was in the azathioprine arm (azathioprine < intravenous cyclophosphamide < mycophenolate mofetil) and there was a significant difference between the azathioprine and mycophenolate mofetil arms, favouring azathioprine.

In a Cochrane systematic review<sup>52</sup> of these two studies comparing mycophenolate mofetil with azathioprine,<sup>53,71</sup> the combined data showed that azathioprine had a significantly better corticosteroid-sparing effect, measured as cumulative corticosteroid dose. However, they concluded that the Beisert *et al.* study<sup>71</sup> showed that mycophenolate mofetil was more effective than azathioprine at achieving a higher proportion of patients with disease control.<sup>52</sup>

### 18.2 Azathioprine and oral cyclophosphamide

A retrospective study of 101 patients included 20 treated with prednisolone alone and three groups treated with combinations of prednisolone and immunomodulatory drugs: 51 treated with cyclophosphamide 100 mg daily (1.1–1.5 mg kg<sup>-1</sup>), 16 with azathioprine (100 mg daily initial dose) and 14 with ciclosporin (2.5–3 mg kg<sup>-1</sup> per day). The time to clinical remission was significantly shorter in the cyclophosphamide arm compared with the other three groups. The cyclophosphamide group also had a lower cumulative corticosteroid dose and a shorter time to immunological remission (no detectable antibodies). This study suggests that cyclophosphamide plus prednisolone is more effective than prednisolone alone and is superior to azathioprine plus prednisolone and ciclosporin plus prednisolone.<sup>94</sup>

### 18.3 Azathioprine and intravenous cyclophosphamide

In a small, multicentre RCT of 22 patients with pemphigus (16 PV) a regimen of oral methylprednisolone (initial dose 2 mg kg<sup>-1</sup>) and azathioprine (2–2.5 mg kg<sup>-1</sup>) was compared with a DCP regimen. The DCP regimen comprised pulses of 3 × 100-mg intravenous dexamethasone and 500-mg intravenous cyclophosphamide on day 1, repeated every 2–

3 weeks initially, dropping down in frequency to every 6 weeks. Oral cyclophosphamide 50 mg daily was given between pulses but stopped after 6 months. Cyclophosphamide pulses were stopped when there was no relapse at 6 weeks from the last dose, but dexamethasone pulses were continued every 12 weeks. Patients were followed up for 2 years and there were no significant differences in either efficacy or adverse effects in the two treatment arms.<sup>70</sup>

Another study has compared a modified DCP regimen (each course included 1000-mg intravenous methylprednisolone for 4 days plus 500-mg intravenous cyclophosphamide for 1 day) with oral prednisolone (1–2 mg kg<sup>-1</sup> initial dose) plus azathioprine (100–150 mg daily). Only three monthly pulses were given, with oral cyclophosphamide 50 mg daily and oral prednisolone, initially 30 mg daily, between pulses. It was not randomized, with 72 patients in the pulse arm and 51 in the control arm. Most outcome measures were similar in both groups, although at 1 year, cumulative corticosteroid doses and weight gain were significantly greater in the azathioprine arm, suggesting superiority of the DCP regimen compared with oral prednisolone and azathioprine.<sup>72</sup>

In the nonblind single-centre RCT that recruited 120 patients with PV and is described in section 18.1, efficacy and adverse effects were similar in the pulsed cyclophosphamide and azathioprine arms.<sup>53</sup> The cumulative corticosteroid dose was lower in the azathioprine arm but it was not significantly different from that in the cyclophosphamide arm. However, a Cochrane systematic review of these data indicated that the difference in cumulative corticosteroid dose was significant, favouring azathioprine as an adjuvant drug.<sup>52</sup>

#### 18.4 Intravenous cyclophosphamide and mycophenolate mofetil

Only one study comparing cyclophosphamide pulses with mycophenolate mofetil has been described (see section 18.1). In this study 30 patients with PV were recruited to each arm. There were no significant differences in efficacy or adverse events.<sup>53</sup> Both arms showed a corticosteroid-sparing effect, measured as cumulative prednisolone dose, but the difference between the cumulative corticosteroid dose in the two arms was reported by the authors as not significant using ANOVA. A Cochrane systematic review of these data indicated that the difference in cumulative corticosteroid dose was significant, favouring pulsed cyclophosphamide as an adjuvant drug.<sup>52</sup>

### 19.0 Topical therapy for the skin (Level of evidence 1–)

PV is managed largely with systemic therapy. However, high-quality skincare is essential and adjuvant topical therapy, including topical corticosteroids, may be of additional benefit, although there are no controlled studies to confirm this. Rarely, patients with mild disease, particularly if confined to the mucosal surfaces, can be managed on topical therapy alone. Huilgol and Black have reviewed topical therapy for

pemphigus and pemphigoid in detail.<sup>229,230</sup> Topical tacrolimus ointment 0.1% in combination with systemic treatment has been reported to heal recalcitrant facial erosions.<sup>231</sup> A small, randomized double-blind clinical trial (11 patients, 62 lesions) demonstrated significant benefit of pimecrolimus 1% cream over placebo for the healing of cutaneous erosions. The patients were also receiving systemic immunosuppression.<sup>232</sup>

Other small randomized trials treating cutaneous lesions have suggested benefit from pilocarpine gel 4%,<sup>233</sup> nicotinamide gel 4%,<sup>234</sup> and epidermal growth factor (10 µg g<sup>-1</sup>) in 0.1% sulfadiazine cream.<sup>235</sup> Scalp lesions can be particularly persistent and are often covered in thick crust rather than being eroded. Soaking the crust in emollient or oil followed by gentle washing to remove the crust allows topical corticosteroids to penetrate better. Corticosteroid scalp preparations in an alcohol base should be avoided because they sting; lotions or creams should be used instead. Nasal lesions can be managed with topical corticosteroid nasal preparations such as fluticasone propionate nasules 400 µg twice daily.

### 20.0 Oral management (Strength of recommendation D, Level of evidence 3)

Oral lesions in PV are characterized by painful ulceration involving any surface of the oral cavity. The buccal mucosa, soft palate, lips and tongue are most frequently affected. Painful erosions on the gingival margins may inhibit tooth brushing resulting in an accumulation of plaque. This compounds the pain and inflammation. Furthermore, patients with PV have a worse periodontal status than seen in matched controls.<sup>236,237</sup>

#### 20.1 Topical corticosteroid preparations

These are frequently used as adjunctive therapy. However, as most patients are on concomitant systemic therapy, evidence for the additional benefit of topical treatments is poor. Nevertheless, topical corticosteroid preparations are often used in patients with mucosal PV and include corticosteroid mouthwashes such as betamethasone sodium phosphate 0.5 mg dissolved in 10 mL of water as a 2–3-min rinse-and-spit solution one to four times a day, fluticasone propionate nasules diluted in 10 mL of water twice daily or clobetasol 0.05% ointment mixed in 50% Orabase<sup>®</sup> twice weekly applied to localized lesions on a dried mucosa. The latter can be mixed together by the patient and stored in the fridge.

#### 20.2 Tacrolimus

In a split-mouth (two treatments compared when applied to one or other side of the mouth at the same time) randomized trial over 2 weeks (n = 15) the efficacy of triamcinolone acetonide 0.1% paste was compared with tacrolimus 0.1% ointment. The degree of mucosal involvement and pain scores were significantly reduced in both treatments compared with baseline but there was no difference between the

treatments.<sup>238</sup> Topical tacrolimus, applied twice daily for 4 weeks, was beneficial in one case of recalcitrant PV affecting the lips.<sup>239</sup>

### 20.3 Topical ciclosporin

There are small numbers of reports indicating that topical ciclosporin is effective for the oral lesions of PV. A 5-mL (500-mg) oral suspension used three times a day for 2 months in oral pemphigus ( $n = 12$ ) recalcitrant to conventional treatment was reported to result in significant improvement in both symptoms and signs of PV.<sup>240</sup>

Ciclosporin mouthwash ( $100 \text{ mg mL}^{-1}$ ) 5 mL used three times per day was effective within 6 months in a patient with recalcitrant oral lesions for 20 years.<sup>241</sup> Treatment was reduced and the patient was maintained on a once-daily mouthwash for 5 years. In a further three patients with PV, 67% (two of three) had a clinical improvement.<sup>242</sup> However, topical ciclosporin tastes unpleasant and is relatively expensive.<sup>242</sup>

### 20.4 Intralesional triamcinolone

Mignogna *et al.* evaluated the efficacy of perilesional/intralesional triamcinolone acetonide injections in oral PV in addition to conventional immunosuppressive therapy plus topical corticosteroid ( $n = 16$ ) in an open-label trial.<sup>243</sup> In comparison with a group of patients not receiving injections ( $n = 19$ ), the perilesional/intralesional triamcinolone acetonide group achieved a shorter time to clinical remission (126 vs. 153 days; not statistically significant) and obtained acceptable compliance with this treatment.

### 20.5 Topical prostaglandin E<sub>2</sub>

Topical prostaglandin E<sub>2</sub> applied twice daily in 10 patients with oral lesions in PV resulted in complete healing by 3 months in 30% of patients with PV (three of 10). They had mainly mild disease affecting one mucosal site. A further three patients improved as long as treatment was continued, but relapsed within 7–10 days of stopping therapy, while four of 10 did not improve. Other treatments had been discontinued 2 weeks prior to the study.<sup>244</sup>

## Recommendations for oral treatment

- Maintenance of good oral hygiene is paramount. Use of soft toothbrushes and mild, mint-free toothpaste may be helpful, such as paediatric formulations or Kingfisher Fennel<sup>®</sup>. Regular, 3-monthly attendance to a dental hygienist is recommended. In addition, use of an antiseptic mouthwash two or three times a week, diluted if necessary, may also be helpful. Agents include hydrogen peroxide 1.5%, for example Peroxyl<sup>®</sup> mouthwash, 10 mL twice daily or chlorhexidine digluconate 0.2% mouthwash, such as Corsodyl<sup>®</sup> mouthwash, 5–10 mL twice

weekly. Dilution of mouthwashes (by 50%) may be necessary to reduce discomfort. Barrier preparations such as Gengigel<sup>®</sup> mouth rinse or gel or Gelclair<sup>®</sup> are also helpful for pain control.

- Use of an anti-inflammatory oral rinse or spray containing benzydamine hydrochloride, for example Diffiam<sup>®</sup> oral rinse or spray, may be helpful, particularly before meals. Anaesthetic preparations such as viscous lidocaine 2% gel may also be helpful.
- Patients are susceptible to oral *Candida* and therefore oral swabs or saliva sampling is helpful at each visit. Use of nystatin oral suspension four times a day for 1 week per month may be helpful.
- For multiple oral erosions, mouthwashes are most practical, for example a soluble betamethasone sodium phosphate 0.5 mg tablet dissolved in 10 mL of water may be used up to four times daily, holding the solution in the mouth for about 2–3 min and reducing the frequency as oral lesions improve. Fluticasone propionate nasules (400 µg) similarly mixed in water may also be used two to three times per day. Isolated oral erosions could be treated with application of topical corticosteroid preparation, such as clobetasol propionate 0.05% in a 50 : 50 mix with an adhesive paste, for example Orabase<sup>®</sup>, twice weekly and applied to a dried mucosa at night.
- Perilesional or intralesional triamcinolone acetonide injections may be considered in the maintenance phase of treatment (up to  $25 \text{ mg mL}^{-1}$ ) to localized lesions.

## 21.0 Nursing care

PV has the potential to cause extensive cutaneous erosion, and in very active cases, fragility of normal skin (exhibited by a positive Nikolsky sign). Therefore, careful handling of the skin by specialist dermatology nurses, or other nursing staff familiar with caring for patients with skin failure, is essential. Attention to fluid balance, haemodynamic stability, thermoregulation, prevention of infection, prevention of further skin trauma, pain management, nutritional intake and psychological support is equally important in addition to skincare.<sup>245</sup>

It is recommended that any intact bullae are decompressed by piercing. The blister roof is left *in situ* to act as a biological dressing. A daily blister chart is a useful means of mapping disease progress in the acute phase.<sup>246</sup>

### 21.1 A guide to blister management

Anecdotal experience suggests that aspirating blisters causes more discomfort than piercing them. Table 2 summarizes the management of blisters for all types of bullous disease including PV and epidermolysis bullosa.

The application of a bland emollient, such as 50% white soft paraffin and 50% liquid paraffin, is recommended to support barrier function,<sup>247</sup> reduce transcutaneous water loss and encourage re-epithelialization.<sup>248,249</sup> This should be applied to

Table 2 Management of blisters

1. Gently cleanse blister with antimicrobial solution, taking care not to rupture
2. Pierce blister at base with a sterile needle, with the bevel facing up. Select a site in which the fluid will drain out by gravity to discourage refilling
3. Gently apply pressure with sterile gauze swabs to facilitate drainage and absorb fluid
4. Do not derroof the blister
5. After fluid has drained, gently cleanse again with an antimicrobial solution
6. It may be necessary to apply a nonadherent dressing
7. Some large blisters may need a larger hole to drain properly – use a larger needle and pierce more than once
8. Many patients report pain or a burning sensation during blister care; offer analgesia prior to the start of the procedure
9. Document on blister chart the number and location of new blisters

the whole skin including erosions. Products containing irritants and sensitizers should be avoided. To reduce the shearing forces and pain associated with application of emollients to erosions, a 50 : 50 aerosolized preparation of white soft paraffin:liquid paraffin can be used to supplement application of the ointment form. Emollients can be applied directly to the skin or initially to primary dressings.

Potassium permanganate soaks (one Permatab<sup>®</sup> – 400 mg – in 4 L of water, i.e. a 1 : 10 000 solution) may be helpful for wet, weepy erosions. The solution should not be applied for longer than 15 min as it becomes ineffective due to oxidation. If practical, soaking in a bath is an effective way of treating large areas. Alternatively, it can be applied by soaking gauze swabs or dressing pads and applying to affected areas. The patient should be counselled regarding temporary skin discoloration. Nails should be covered with white/yellow soft paraffin to help prevent nail discoloration.<sup>250–252</sup>

There is no clear evidence regarding the superiority of any particular dressing in PV, but those used should be nonadherent.<sup>253</sup> The application of an emollient and dressing to eroded areas helps reduce fluid and protein loss, reduces the risk of secondary infection and assists with pain control. A soft silicone mesh dressing, such as Mepitel<sup>®</sup>, is a suitable primary dressing, and it can be coated (spread) with an appropriate emollient such as a 50 : 50 mix of liquid paraffin and white soft paraffin, or a topical antimicrobial if appropriate, prior to application to the skin. The secondary dressing usually needs to be absorbent, such as a soft silicone foam or other foam dressing, for example Mepilex<sup>®</sup> or Allewyn<sup>®</sup>.<sup>253</sup> These dressings can be secured to the trunk or the limbs with soft knitted tube dressings such as Comfast<sup>®</sup>.

When dressings are removed, if they have dried onto the skin, they should be soaked off to minimize pain and avoid further damage.<sup>254</sup> There is no evidence regarding the optimal frequency of dressing changes, but one should consider the appearance of strikethrough on the secondary dressing, the

need to assess for evidence of infection and the stage of wound healing. In the acute stage, dressings should be changed daily to assess them. It may be appropriate in the later stages of healing to change only the secondary dressing but leave the primary dressing in situ, with the underlying erosion left undisturbed. Further applications of topical agents can be placed on top of the silicon mesh primary dressing in this situation. Crusts should be removed to promote healing. All patients with pemphigus should be nursed on an appropriate pressure-relieving mattress regardless of the degree of skin failure as they are prone to developing pressure areas by virtue of the disease.<sup>255</sup>

Infection and sepsis are a significant risk and a major cause of mortality in PV, so vigilance in detecting signs of infection is essential.<sup>256</sup> Infection also increases the risk of scarring. Daily washing with an antibacterial product can decrease colonization. Dressings should be changed using an aseptic technique and patients with extensive erosions barrier nursed. Erosions showing clinical signs of infection should have bacterial and viral swabs sent. It may be appropriate to apply topical antimicrobials for short periods only. Systemic antibiotics should be used if there are local or systemic signs of infection or extending infection of the skin. Local policy should guide the choice of antibiotic agent.

Pain control is essential, and attention needs to be paid to both acute and maintenance (background) analgesia with the ability to provide timely additional short-term boosts when needed, for example with dressing changes. The advice of a pain team may be necessary.

## 22.0 Pemphigus in pregnancy (Level of evidence 3)

This is a rare occurrence requiring close cooperation between dermatologist, obstetrician and neonatologist. Careful selection and monitoring of immunosuppression during pregnancy is required. Due to the passive transfer of maternal IgG autoantibodies across the placenta, the neonate may be affected by cutaneous erosions. In 2009, Kardos *et al.* published a review of 38 reports describing 49 pregnancies affected by pemphigus.<sup>257</sup> Prednisolone alone was used in 76% (37 of 49) of the cases at doses of 5–300 mg per day. Adjuvant therapies were used in eight patients: azathioprine (n = 5), plasmapheresis (n = 1), plasma exchange (n = 1) and dapsone (n = 1). Five neonatal deaths were reported. Twenty (45%) of the neonates had pemphigus lesions at birth, with all resolving within 4 weeks either spontaneously or with mild topical corticosteroids. Overall, there seems to be an increased risk of fetal morbidity with gestational PV, with higher preterm birth rates and low birthweight. There is no clear increased fetal loss.<sup>258</sup>

The most commonly used treatments for pemphigus in pregnancy are oral corticosteroids. Current evidence suggests that there is no significant increased risk of stillbirth, preterm delivery or congenital malformations from using prednisolone in any disease, although the usual side-effects of corticosteroid use will still occur.<sup>258</sup> Both systemic and very potent topical

corticosteroids have been linked with intrauterine growth retardation. Corticosteroids should be the first-line systemic agent. The type of corticosteroid used is important, as prednisolone is 90% inactivated by the placenta, whereas betamethasone and dexamethasone are far less inactivated and could have a greater effect on the fetus.

There are no prospective studies of immunosuppressant therapy for pemphigus in pregnancy. Many systemic immunosuppressive agents including mycophenolate mofetil, methotrexate and cyclophosphamide should be avoided due to known risks to the fetus.

Azathioprine, in combination with corticosteroids, has been used successfully for pemphigus in pregnancy.<sup>257</sup> While there are risks of teratogenicity with azathioprine, these are low and azathioprine has been widely used during pregnancy in association with renal transplantation, inflammatory bowel disease and systemic lupus erythematosus.<sup>259</sup>

IVIg is safe in pregnancy. Ahmed and Gürçan reported eight patients with severe pemphigus in pregnancy. Seven responded well and one developed headaches and stopped treatment; none of the neonates had any erosions.<sup>159</sup> Finally, plasmapheresis has been used successfully, although this option is unavailable in many centres.<sup>260</sup>

Rituximab has been used successfully in childhood pemphigus, although its effects in pregnancy are uncertain.<sup>261–263</sup> Rituximab is able to cross the maternofetal barrier and the manufacturers advise against pregnancy for 1 year following rituximab therapy. The drug may potentially affect the developing immune system, and thus the risks to mother and fetus need to be considered carefully prior to treatment. If a pregnancy is exposed to rituximab the baby should avoid live vaccines for at least the first 6 months of life.<sup>264</sup>

Maternal IgG is excreted in human milk and women should not breastfeed while receiving rituximab and for up to 12 months following the last infusion.

## Summary

Pemphigus occurring in pregnancy is rare. Data suggest that there is no increased risk of fetal loss, although some morbidity is seen especially with respect to low birthweight. Prednisolone alone is the most common treatment. Certain second-line treatments have been safely used when needed.

## 23.0 Pemphigus vulgaris in children (Strength of recommendation D, Level of evidence 3)

Even though PV affects adults predominantly, it can occur in children. A review suggested a further subdivision of this group into childhood PV, referring to disease in children aged < 12 years, and juvenile PV, affecting adolescents aged 12–18 years.<sup>265</sup> This subclassification helps delineate the potential adverse effects of medications used in these subgroups. A self-limiting form of PV can occur in neonates born to mothers with PV, due to transplacental transfer of autoantibodies.

Systemic corticosteroids are the treatment of choice in both childhood and juvenile PV,<sup>67</sup> but children are more susceptible than adults to the potential adverse effects of corticosteroids. Growth retardation is the most important adverse effect in children on long-term oral corticosteroids. In both children and adolescents, the height will need to be recorded regularly and expert advice is prudent if high-dose corticosteroids are used long term. Regular checks for signs of adrenal suppression are recommended.<sup>266</sup>

In a series of 33 patients with childhood PV, prednisone was used in 26, with the dose ranging from 12 to 500 mg per day (mean 88.3). Other immunosuppressant medications used included gold (n = 2), azathioprine (n = 6), dapsone (n = 4), cyclophosphamide (n = 2), ciclosporin (n = 1), rituximab (n = 2), mycophenolate mofetil (n = 1) and IVIg (n = 1). Six patients (18%) achieved complete recovery and 79% (26 of 33) had partial remission, with minor relapses while on maintenance therapy. Of concern was the high rate of serious side-effects, with cushingoid features in 65%, growth retardation in 50% and infection in 50%.<sup>267</sup>

Juvenile PV has features similar to adult PV, but disruption of biological and social development due to the skin disease raises particular concern during adolescence. The largest series of juvenile PV included 47 patients, with 42 requiring systemic corticosteroids. Corticosteroid-sparing agents used included azathioprine (n = 1), intramuscular gold (n = 1), dapsone (n = 3), cyclophosphamide (n = 2), mycophenolate mofetil (n = 2) and rituximab (n = 3). IVIg was reported in eight patients, for four of whom it was used as monotherapy. All 47 patients responded to treatment, with adverse effects reported in 19%. Infection (9%), weight gain (11%) and cushingoid appearance (6%) were the main side-effects, associated mainly with systemic corticosteroids.<sup>67,268</sup> Relative youth may be a positive factor in terms of prognosis and mortality.<sup>268</sup>

There have been only 18 anecdotal reports of the use of rituximab in PV affecting children.<sup>263,269–272</sup> It may have a role in childhood PV when treatment with systemic corticosteroids and other immunosuppressants has failed to confer any benefit. It has been used as monotherapy or in combination with systemic corticosteroids and other immunomodulatory drugs.

IVIg therapy has been reported to be effective in children with juvenile PV.<sup>273,274</sup> It can be used as monotherapy or in combination with other systemic agents.<sup>268</sup> IVIg is an attractive second-line option for juvenile PV as the risks of thromboembolic events and renal failure are considered to be much less compared with adults.<sup>274</sup>

## Summary

The course of PV in children is generally favourable, with a better prognosis compared with adult PV.<sup>263</sup> Due to its rarity, there are no RCTs in the use of systemic agents in this condition. Overall, its treatment after initial systemic corticosteroids is similar to adult regimens and the same adjuvant therapies can be used.

## 24.0 Induced pemphigus vulgaris

Drugs can trigger pemphigus but this is uncommon. The diagnosis is challenging because drug-induced cases resemble idiopathic pemphigus, there are no clinical or laboratory tests that can distinguish them reliably and the latency between starting the drug and disease onset can be several months. Therefore, a thorough drug history is essential, cross-checking against drugs reputed to trigger pemphigus (Table 3).<sup>275,276</sup> A poor response to standard systemic treatments should also alert to the possibility of drug-induced pemphigus (DIP).

There are three groups of chemical structures that have been suggested to cause drug-induced pemphigus: thiol drugs, which have a sulfhydryl radical, phenol drugs and nonthiol, nonphenol drugs (Table 3). PF is the most common pattern of DIP, observed in up to 70% of thiol-induced cases. Non-thiol drugs tend to trigger a PV phenotype. Pruritus is more common in DIP than in idiopathic pemphigus.<sup>275,277</sup> Diagnostic investigations are as for idiopathic pemphigus, with no immunopathological features in routine investigations that differentiate.<sup>278</sup>

Initial management of DIP includes stopping the offending drug, possibly combined with conventional treatment in severe cases to hasten remission. Thereafter, it may follow two courses: the disease may continue in 50% in spite of drug withdrawal (DIP) while others recover completely (drug-triggered pemphigus).<sup>279</sup> Recovery following drug withdrawal is more likely in thiol-triggered cases. In patients who do not remit upon drug withdrawal, the course and prognosis are similar to those in idiopathic disease and should be managed as such.

## 25.0 Patient support

Patients should be directed towards reputable sources of information and support. A patient information leaflet is available on the BAD website ([www.bad.org.uk/for-the-public/patient-information-leaflets](http://www.bad.org.uk/for-the-public/patient-information-leaflets)). In the U.K., the PV Network ([www.pemphigus.org.uk](http://www.pemphigus.org.uk)) and PEM Friends (U.K.) ([www.pemfriends.co.uk](http://www.pemfriends.co.uk)), and internationally the Pemphigus Pemphigoid Foundation ([www.pemphigus.org](http://www.pemphigus.org)), are organizations providing patient support. Patients with PV may need psychological support to help them cope with coming to terms with a chronic, painful and visible disease or the impact of its treatment,

**Table 3** Drugs reputed to trigger pemphigus<sup>275,276</sup>

Thiol drugs	Phenol drugs	Nonthiol, nonphenol drugs
Captopril	Cefadroxil	Calcium channel blockers
D-Penicillamine	Rifampicin	Angiotensin-converting enzyme inhibitors
Gold	Levodopa	Nonsteroidal anti-inflammatory drugs
Carbimazole	Aspirin	Progesterone
Penicillin	Heroin	Glibenclamide
Piroxicam	Phenobarbital	Pyrazolone derivatives

particularly corticosteroids.<sup>280,281</sup> The input of a pain management team may be needed to advise on management of painful skin or mucosal lesions, and the advice of a dietician if oral intake is impaired.

## 26.0 Follow-up and tapering of treatment

Once remission is induced, there should follow a period of maintenance treatment using the minimum drug doses required for disease control and during which occasional blisters are acceptable. Drug doses should be reduced slowly (see section 12) and patients should remain under follow-up while they remain on therapy. Ultimately, treatment may be withdrawn if there has been prolonged clinical remission. The chances of relapse are reduced if immunofluorescence or ELISA studies are negative, for example the risk of relapse is 13–46% if DIF is negative, 44–100% if DIF is positive, 24% if IIF is negative, 57% if IIF is positive,<sup>282–284</sup> 25% if desmoglein 3 ELISA is negative and 56% if desmoglein 3 ELISA is positive.<sup>285</sup>

In DIF-negative patients, there is some evidence to suggest that relapse is less likely the longer a patient has been in remission on minimal therapy prior to stopping treatment: 46% in all DIF-negative patients, 22% in those in remission for 6 months and 0% with remission of over 12 months.<sup>284</sup> However, DIF can remain positive occasionally in patients who are in remission and off all treatment.<sup>21</sup> A less invasive and relatively simple alternative to DIF on a skin biopsy, in this situation, is DIF on the outer root sheath of plucked hairs.<sup>286</sup> However, this investigation is not widely available at present.

There is no evidence to guide the order in which treatments are reduced and withdrawn in PV. However, it is common practice to withdraw corticosteroids first,<sup>287,288</sup> to minimize their side-effects, while maintaining adjuvant immunosuppressants at full dose (see section 12 for guidance on the rate of dose reduction). Thereafter, adjuvant drugs can be tapered slowly if remission is maintained. If complete treatment withdrawal is successful, and the patient remains in complete remission for a prolonged period, discharge to their primary-care physician is reasonable, but patients and their carers should be warned that PV can recur, in which case they should be referred to secondary care immediately.

## 27.0 Future directions

As these guidelines illustrate, there is a lack of high-quality evidence supporting the use of many drugs in PV. Even answering the basic question of whether there is benefit in adding adjuvant immunosuppressants to corticosteroids is not clear-cut for most drugs. The answers to these questions will only come from large, multicentre RCTs, which would need to be of sufficient length to demonstrate the long-term outcomes that are of relevance in this chronic disease.

The role of biologics and their place in the management of PV is an area of great interest. Most experience comes from treating patients with established disease resistant to standard

Table 4 Summary of treatment options for the management of pemphigus vulgaris (PV)

Strength of recommendation (level of evidence) <sup>a</sup>	Drug	Indication(s)	Advantages	Disadvantages	Principal side-effects
B (1+)	Oral corticosteroids	The cornerstone of therapy; effective; optimum dosing schedule not known	Effective; rapid onset; oral administration; inexpensive	Side-effect profile	Diabetes; osteoporosis; adrenal suppression; peptic ulceration; weight gain; increased susceptibility to infection; mood changes; proximal myopathy; Cushing syndrome; cataracts
B (1+)	Azathioprine	Commonly used in combination with oral corticosteroids for steroid-sparing effect; monotherapy may be possible for mild disease	Oral administration; inexpensive	Slow onset; side-effect profile	Myelosuppression and nausea (related to thiopurine methyltransferase activity); hepatotoxicity and hypersensitivity reactions (unrelated to thiopurine methyltransferase activity); increased susceptibility to infection
B (1+)	Mycophenolate mofetil	An alternative to azathioprine and cyclophosphamide	Generally well tolerated and possibly less toxic than other immunosuppressive agents	Slow onset	Gastrointestinal disturbances (mycophenolic acid may be used as an alternative); lymphopenia; anaemia; neutropenia; thrombocytopenia; increased risk of infections
B (1+)	Rituximab	Patients intolerant of or refractory to conventional corticosteroids together with adjuvant immunosuppression	Effective; long-lasting effect	Cost; infection risk; infusion reactions <sup>b</sup>	Risk of infection; risk of reactivation of hepatitis B; risk of precipitation of progressive multifocal leucoencephalopathy due to the JC virus.
B (2+)	Pulsed cyclophosphamide and dexamethasone or methylprednisolone	Consider for severe or recalcitrant PV; repeated courses; may not be practical	Possibly fewer steroid side-effects than conventional corticosteroid therapy	Intravenous administration; labour intensive; risk of bladder malignancy and infertility	Hypogammaglobulinaemia (rare); late-onset neutropenia; development of neutralizing antibodies. Infusion reactions are generally mild; anaphylaxis is rare Alopecia, infections; infertility; haemorrhagic cystitis; acne; hiccup

(continued)

**Table 4** (continued)

Strength of recommendation (level of evidence) <sup>a</sup>	Drug	Indication(s)	Advantages	Disadvantages	Principal side-effects
B (2++)	Intravenous immunoglobulin	Possible adjuvant maintenance agent for recalcitrant PV failed on other regimens; could be considered in severe cases to induce remission while slower-acting drugs take effect	Rapid action reported in some cases; no increased risk of opportunistic infection	Intravenous administration; very expensive; labour intensive; theoretical risk of blood-borne virus infections	During infusion, chills, tachycardia, hypotension, muscle pains, pyrexia, nausea and headache are common, self-limited and respond to slowing the infusion; anaphylaxis is rare (increased risk in IgA deficiency)
D (3)	Extracorporeal photopheresis	May be considered in recalcitrant disease where conventional treatment has failed	Can be performed via peripheral venous access	Specialist equipment; trained staff; labour intensive; expensive; limited availability; limited data; ultraviolet protective sunglasses on the day of treatment; venous access can be a problem	Symptoms of hypovolaemia during procedure
D (3)	Immunoadsorption	Should be reserved for the treatment of patients resistant to or intolerant of other approaches and should be used in combination with treatment directed at suppressing new antibody formation	Rational therapy aimed at rapidly decreasing pathogenic antibody levels; generally well tolerated	Expensive; inconvenient; rebound antibody production	Hypotension; anaphylaxis; sepsis
D (3)	Methotrexate	Could be used as an adjuvant drug if others are poorly tolerated, contraindicated or ineffective	Oral administration; inexpensive; dermatologists very familiar with it	Slow onset	Myelosuppression; hepatotoxicity; pneumonitis
D (3)	Oral cyclophosphamide	Could be considered as an alternative to azathioprine and mycophenolate mofetil if secondary infertility is not a concern	Inexpensive; oral administration	Potential risk of haemorrhagic cystitis and carcinoma of bladder	Neutropenia; alopecia; gastrointestinal disturbances; raised transaminases; thrombocytopenia; secondary infertility; nausea
D (3)	Plasma exchange and plasmapheresis	Not recommended as routine; may be considered for difficult cases if combined with steroids and immunosuppressants	Direct and immediate removal of IgG and therefore removal of PV antibodies	Central venous access; specialist equipment; trained staff; limited availability; labour intensive; expensive; rebound production of PV antibodies after plasma exchange	Septicaemia; fluid and electrolyte imbalance

(continued)

Table 4 (continued)

Strength of recommendation (level of evidence) <sup>a</sup>	Drug	Indication(s)	Advantages	Disadvantages	Principal side-effects
D (3), historical treatment	Gold	More commonly used as an adjuvant, enabling steroid dose reduction; an alternative to more established adjuvant drugs	Inexpensive	Intramuscular administration; slow onset; not commonly used	Rashes; nephrotic syndrome; myelosuppression; hypersensitivity syndromes
D (good practice point) (4)	Pulsed intravenous corticosteroids	Consider for remission induction in severe or recalcitrant disease, particularly if unresponsive to high oral doses	Rapid onset; inexpensive	Intravenous administration	Mood changes; flushing
Not recommended (1–)	Ciclosporin			Side-effects; expensive	Hypertension; renal impairment; gastrointestinal disturbances; hypertrichosis; hypertrophic gingivitis
Insufficient evidence (3)	Chlorambucil	Although it may be used in practice, further study is needed before recommendation	Oral administration; inexpensive	Minimal data	Myelosuppression
Insufficient evidence (1–)	Dapsone	Although it may be used in practice, further study is needed before recommendation	Inexpensive	Minimal data	Haemolysis; methaemoglobinemia; hypersensitivity reactions
Insufficient evidence (2–)	Sulfasalazine or pentoxifylline	Although it may be used in practice, further study is needed before recommendation	Oral administration; inexpensive	Frequent dosing (two tablets twice daily)	Gastric pain; nausea and headache
Insufficient evidence (3)	Tetracyclines and nicotinamide	Tetracycline/nicotinamide could be considered as an adjuvant in milder PV	Inexpensive	Lots of tablets	Flushing and headaches due to vasodilation with nicotinamide; gastrointestinal upset (tetracyclines); hyperpigmentation, particularly at sites of blistering (minocycline); discoloration of teeth (avoid tetracyclines in children and pregnant or lactating women)

<sup>a</sup>See the Appendices for definitions. <sup>b</sup>See Appendix S2; Supporting Information.

treatment. It is interesting to speculate whether using rituximab, or newer anti-CD20 drugs, as a first-line drug in newly presenting, treatment-naïve patients might offer better long-term outcomes than the standard approach of corticosteroids with an adjuvant immunosuppressant. Such potential advantages might offset its additional cost in the long-term. A recent unblinded RCT has shown that rituximab combined with prednisolone is more effective than prednisolone only in newly diagnosed patients.<sup>45</sup> Further studies to confirm this result and to compare with corticosteroid-immunosuppressant combinations are awaited.

The development of anti-CD20 drugs that can be self-administered by subcutaneous injection also has the potential to be a very useful step forward. At present, ongoing trials using rituximab and ofatumumab may help answer some of these questions, and positive results may lead to formal licensing, making use of these drugs more straightforward. In 2016, NHS England approved routine commissioning of rituximab in the treatment of pemphigus that has failed to respond to systemic steroids together with adjuvant immunosuppressive agents such as mycophenolate or azathioprine,<sup>289</sup> thereby ensuring consistent access and funding across the NHS in England. This document was produced prior to the recent RCT using rituximab.<sup>45</sup>

Further investment in diagnostic laboratories is needed to enable routine use of tests such as immunoprecipitation to enable more precise diagnosis of pemphigus subtypes leading to better targeted investigation and treatment.

## 28.0 Recommended audit points

In the last 20 consecutive patients with PV, or all patients seen in the last 12 months (if fewer than 20), is there clear documentation of

- 1 Measurement of baseline parameters prior to starting treatment.  
As a minimum this should include
  - o Weight
  - o Blood pressure and whether there is a clinical history of hypertension
  - o Height (children)
  - o Blood glucose and HbA1c and whether there is a clinical history of diabetes
  - o Pregnancy test (if appropriate)
  - o Full blood count, renal and liver function tests.
- 2 Appropriate investigations to establish diagnosis.  
As a minimum this should include
  - o A lesional skin/mucosal biopsy for routine histopathology
  - o Perilesional skin/mucosal biopsy for DIF (alternatively, IIF or desmoglein ELISA if biopsy is not possible).
- 3 Evidence of appropriate drug monitoring.  
For patients on corticosteroids, as a minimum this should include regular measurements of or documentation of

- o Blood pressure
- o Weight
- o Blood glucose/HbA1c
- o Height (children)
- o Renal function
- o Evidence that gastric and bone prophylaxis is considered
- o Symptoms suggestive of important side-effects, for example peptic ulceration or visual decline.  
Other investigations are dependent on the choice of adjuvant drug but should include documentation of baseline investigations relevant to the drug in question and evidence of appropriate follow-up monitoring.

- 4 Adherence to guidelines for prophylaxis and management of steroid-induced osteoporosis.<sup>82</sup>
- 5 Use of objective disease-scoring methodologies to assess clinical outcomes, for example PDAI, ABSIS or the Oral Disease Severity Score.<sup>31–35</sup>

The usual audit recommendation of 20 cases per department is to reduce variation in the results due to a single patient, and to allow benchmarking between different units. However, departments unable to achieve this recommendation may choose to audit all cases seen in the preceding 12 months.

## 29.0 Summary

The full manuscript provides details of the evidence. Table 4 summarizes the treatment options for PV, highlighting certain practical and economic considerations. For an overview of PV management to serve as a brief summary of options for reference in the clinical setting see Table 1.

## Acknowledgments

We are very grateful to everyone who commented on the draft during the consultation period.

## References

- 1 Bell HK, Ormerod AD. Writing a British Association of Dermatologists clinical guideline: an update on the process and guidance for authors. *Br J Dermatol* 2009; **160**:725–8.
- 2 Brouwers MC, Kho ME, Browman GP *et al.* AGREE II: advancing guideline development, reporting and evaluation in health care. *CMAJ* 2010; **182**:E839–42.
- 3 Amagai M, Hashimoto T, Shimizu N *et al.* Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. *J Clin Invest* 1994; **94**:59–67.
- 4 Emery DJ, Diaz LA, Fairley JA *et al.* Pemphigus foliaceus and pemphigus vulgaris autoantibodies react with the extracellular domain of desmoglein-1. *J Invest Dermatol* 1995; **104**:323–8.
- 5 Harman KE, Gratian MJ, Bhogal BS *et al.* A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype. *Br J Dermatol* 2000; **143**:343–8.

- 6 Saito M, Stahley SN, Caughman CY *et al.* Signaling dependent and independent mechanisms in pemphigus vulgaris blister formation. *PLOS ONE* 2012; **7**:e50696.
- 7 Ding X, Aoki V, Mascaro JM Jr *et al.* Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. *J Invest Dermatol* 1997; **109**:592–6.
- 8 Amagai M, Tsunoda K, Zillikens D *et al.* The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. *J Am Acad Dermatol* 1999; **40**:167–70.
- 9 Bystryń JC, Steinman NM. The adjuvant therapy of pemphigus. An update. *Arch Dermatol* 1996; **132**:203–12.
- 10 Wolf R, Landau M, Tur E *et al.* Early treatment of pemphigus does not improve the prognosis. A review of 53 patients. *J Eur Acad Dermatol Venereol* 1995; **4**:131–6.
- 11 Mourellou O, Chaidemenos GC, Koussidou T *et al.* The treatment of pemphigus vulgaris. Experience with 48 patients seen over an 11-year period. *Br J Dermatol* 1995; **133**:83–7.
- 12 Chams-Davatchi C, Valikhani M, Daneshpazhooh M *et al.* Pemphigus: analysis of 1209 cases. *Int J Dermatol* 2005; **44**:470–6.
- 13 Kavusi S, Daneshpazhooh M, Farahani F *et al.* Outcome of pemphigus vulgaris. *J Eur Acad Dermatol Venereol* 2008; **22**:580–4.
- 14 Ryan JG. Pemphigus. A 20-year survey of experience with 70 cases. *Arch Dermatol* 1971; **104**:14–20.
- 15 Scully C, Paes De Almeida O, Porter SR *et al.* Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. *Br J Dermatol* 1999; **140**:84–9.
- 16 Krain LS. Pemphigus. Epidemiologic and survival characteristics of 59 patients, 1955–1973. *Arch Dermatol* 1974; **110**:862–5.
- 17 Sirois DA, Fatahzadeh M, Roth R *et al.* Diagnostic patterns and delays in pemphigus vulgaris: experience with 99 patients. *Arch Dermatol* 2000; **136**:1569–70.
- 18 Bhogal B, Wojnarowska F, Black MM *et al.* The distribution of immunoglobulins and the C3 component of complement in multiple biopsies from the uninvolved and perilesional skin in pemphigus. *Clin Exp Dermatol* 1986; **11**:49–53.
- 19 Bhogal BS, Black MM. Diagnosis, diagnostic and research techniques. In: *Management of Blistering Diseases* (Wojnarowska F, Briggman RA, eds). London: Chapman & Hall, 1990; 15–34.
- 20 Judd KP, Lever WF. Correlation of antibodies in skin and serum with disease severity in pemphigus. *Arch Dermatol* 1979; **115**:428–32.
- 21 Lever WF. Pemphigus and pemphigoid. A review of the advances made since 1964. *J Am Acad Dermatol* 1979; **1**:2–31.
- 22 Amagai M, Komai A, Hashimoto T *et al.* Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. *Br J Dermatol* 1999; **140**:351–7.
- 23 Harman KE, Gratian MJ, Seed PT *et al.* Diagnosis of pemphigus by ELISA: a critical evaluation of two ELISAs for the detection of antibodies to the major pemphigus antigens, desmoglein 1 and 3. *Clin Exp Dermatol* 2000; **25**:236–40.
- 24 Ng PP, Thng ST, Mohamed K *et al.* Comparison of desmoglein ELISA and indirect immunofluorescence using two substrates (monkey oesophagus and normal human skin) in the diagnosis of pemphigus. *Australas J Dermatol* 2005; **46**:239–41.
- 25 Giurdanella F, Diercks GF, Jonkman MF, Pas HH. Laboratory diagnosis of pemphigus: direct immunofluorescence remains the gold standard. *Br J Dermatol* 2016; **175**:185–6.
- 26 Ali S, Kelly C, Challacombe SJ *et al.* Serum and salivary IgG and IgA antibodies to Dsg3 in mucosal pemphigus vulgaris. *Br J Dermatol* 2016; **175**:113–21.
- 27 Chryssomallis F, Dimitriades A, Chaidemenos GC *et al.* Steroid-pulse therapy in pemphigus vulgaris long term follow-up. *Int J Dermatol* 1995; **34**:438–42.
- 28 Patel AN, Simpson RC, Cohen SN. In a patient with an immunobullous disorder, is transportation of the skin biopsy in normal saline adequate for direct immunofluorescence analysis? A critically appraised topic. *Br J Dermatol* 2013; **169**:6–10.
- 29 Vodegel RM, de Jong MC, Meijer HJ *et al.* Enhanced diagnostic immunofluorescence using biopsies transported in saline. *BMC Dermatol* 2004; **4**:10.
- 30 National Institute for Health and Care Excellence. Osteoporosis: assessing the risk of fragility fracture. Clinical guideline CG146. Available at: <https://www.nice.org.uk/guidance/cg146> (last accessed 9 August 2017).
- 31 Pfitze M, Niedermeier A, Hertl M *et al.* Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. *Eur J Dermatol* 2007; **17**:4–11.
- 32 Rosenbach M, Murrell DF, Bystryń JC *et al.* Reliability and convergent validity of two outcome instruments for pemphigus. *J Invest Dermatol* 2009; **129**:2404–10.
- 33 Daniel BS, Hertl M, Werth VP *et al.* Severity score indexes for blistering diseases. *Clin Dermatol* 2012; **30**:108–13.
- 34 Rahbar Z, Daneshpazhooh M, Mirshams-Shahshahani M *et al.* Pemphigus disease activity measurements: Pemphigus Disease Area Index, Autoimmune Bullous Skin Disorder Intensity Score, and Pemphigus Vulgaris Activity Score. *JAMA Dermatol* 2014; **150**:266–72.
- 35 Ormond M, Challacombe SJ, Cook RJ *et al.* An Oral Disease Severity Score (ODSS) validated for pemphigus vulgaris. *Oral Dis* 2016; **22** (Suppl. S2):21.
- 36 Harman KE, Gratian MJ, Bhogal BS *et al.* The use of two substrates to improve the sensitivity of indirect immunofluorescence in the diagnosis of pemphigus. *Br J Dermatol* 2000; **142**:1135–9.
- 37 Harman KE, Seed PT, Gratian MJ *et al.* The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. *Br J Dermatol* 2001; **144**:775–80.
- 38 Sharma VK, Prasad HR, Khandpur S *et al.* Evaluation of desmoglein enzyme-linked immunosorbent assay (ELISA) in Indian patients with pemphigus vulgaris. *Int J Dermatol* 2006; **45**:518–22.
- 39 Kumar B, Arora S, Kumaran MS *et al.* Study of desmoglein 1 and 3 antibody levels in relation to disease severity in Indian patients with pemphigus. *Indian J Dermatol Venereol Leprol* 2006; **72**:203–6.
- 40 Daneshpazhooh M, Chams-Davatchi C, Khamesipour A *et al.* Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity. *J Eur Acad Dermatol Venereol* 2007; **21**:1319–24.
- 41 Schmidt E, Dahnrich C, Rosemann A *et al.* Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. *Exp Dermatol* 2010; **19**:458–63.
- 42 Anand V, Khandpur S, Sharma VK *et al.* Utility of desmoglein ELISA in the clinical correlation and disease monitoring of pemphigus vulgaris. *J Eur Acad Dermatol Venereol* 2012; **26**:1377–83.
- 43 Abasq C, Mouquet H, Gilbert D *et al.* ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. *Arch Dermatol* 2009; **145**:529–35.
- 44 Kwon EJ, Yamagami J, Nishikawa T *et al.* Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission. *J Eur Acad Dermatol Venereol* 2008; **22**:1070–5.
- 45 Joly P, Maho-Vaillant M, Prost-Squarcioni C *et al.* First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. *Lancet* 2017; **389**:2031–40.

- 46 Cheng SW, Kobayashi M, Kinoshita-Kuroda K *et al.* Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. *Br J Dermatol* 2002; **147**:261–5.
- 47 Murrell DF, Dick S, Ahmed AR *et al.* Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. *J Am Acad Dermatol* 2008; **58**:1043–6.
- 48 Martin LK, Werth VP, Villanueva EV *et al.* A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. *J Am Acad Dermatol* 2011; **64**:903–8.
- 49 Martin LK, Murrell DF. Pemphigus: directions for the future. *J Am Acad Dermatol* 2011; **64**:909–10.
- 50 Czernik A, Bystryń JC. Kinetics of response to conventional treatment in patients with pemphigus vulgaris. *Arch Dermatol* 2008; **144**:682–3.
- 51 Mimouni D, Bar H, Gdalevich M *et al.* Pemphigus, analysis of 155 patients. *J Eur Acad Dermatol Venereol* 2010; **24**:947–52.
- 52 Martin LK, Werth V, Villanueva E *et al.* Interventions for pemphigus vulgaris and pemphigus foliaceus. *Cochrane Database Syst Rev* 2009; **1**:CD006263.
- 53 Chams-Davatchi C, Esmaili N, Daneshpazhooh M *et al.* Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. *J Am Acad Dermatol* 2007; **57**:622–8.
- 54 Beissert S, Mimouni D, Kanwar AJ *et al.* Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. *J Invest Dermatol* 2010; **130**:2041–8.
- 55 Atzmony L, Hodak E, Leshem YA *et al.* The role of adjuvant therapy in pemphigus: a systematic review and meta-analysis. *J Am Acad Dermatol* 2015; **73**:264–71.
- 56 Herbst A, Bystryń JC. Patterns of remission in pemphigus vulgaris. *J Am Acad Dermatol* 2000; **42**:422–7.
- 57 Almugairen N, Hospital V, Bedane C *et al.* Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids. *J Am Acad Dermatol* 2013; **69**:583–8.
- 58 Sharma VK, Khandpur S. Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris. *Clin Exp Dermatol* 2013; **38**:659–64.
- 59 Carlson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. *J Am Acad Dermatol* 1996; **34**:645–52.
- 60 Chaidemenos G, Apalla Z, Koussidou T *et al.* High dose oral prednisone vs. prednisone plus azathioprine for the treatment of oral pemphigus: a retrospective, bi-centre, comparative study. *J Eur Acad Dermatol Venereol* 2011; **25**:206–10.
- 61 Ioannides D, Apalla Z, Lazaridou E *et al.* Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study. *J Eur Acad Dermatol Venereol* 2012; **26**:855–60.
- 62 Lever WF, Schaumburg-Lever G. Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. *Arch Dermatol* 1984; **120**:44–7.
- 63 Ratnam KV, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens. A 5-year study. *Int J Dermatol* 1990; **29**:363–7.
- 64 Lapidoth M, David M, Ben-Amitai D *et al.* The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study. *J Am Acad Dermatol* 1994; **30**:752–7.
- 65 Lever WF, White H. Treatment of pemphigus with corticosteroids. Results obtained in 46 patients over a period of 11 years. *Arch Dermatol* 1963; **87**:12–26.
- 66 Katz SI, Halprin KM, Inderbitzin TM. The use of human skin for the detection of anti-epithelial autoantibodies. A diagnostic and prognostic test. *J Invest Dermatol* 1969; **53**:390–9.
- 67 Rosenberg FR, Sanders S, Nelson CT. Pemphigus: a 20-year review of 107 patients treated with corticosteroids. *Arch Dermatol* 1976; **112**:962–70.
- 68 Hirone T. Pemphigus: a survey of 85 patients between 1970 and 1974. *J Dermatol* 1978; **5**:43–7.
- 69 Mimouni D, Nousari CH, Cummins DL *et al.* Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. *J Am Acad Dermatol* 2003; **49**:1059–62.
- 70 Rose E, Wever S, Zilliken D *et al.* Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study. *J Dtsch Dermatol Ges* 2005; **3**:200–6.
- 71 Beissert S, Werfel T, Frieling U *et al.* A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. *Arch Dermatol* 2006; **142**:1447–54.
- 72 Shahidi-Dadras M, Karami A, Toosy P *et al.* Pulse versus oral methylprednisolone therapy in pemphigus vulgaris. *Arch Iran Med* 2007; **10**:1–6.
- 73 Schmidt E, Zillikens D. Diagnosis and treatment of patients with autoimmune bullous disorders in Germany. *Dermatol Clin* 2011; **29**:663–71.
- 74 Lyakhovitsky A, Baum S, Scope A *et al.* The impact of stratifying initial dose of corticosteroids by severity of pemphigus vulgaris on long-term disease severity. *Int J Dermatol* 2011; **50**:1014–19.
- 75 Toth GG, van de Meer JB, Jonkman MF. Dexamethasone pulse therapy in pemphigus. *J Eur Acad Dermatol Venereol* 2002; **16**:607–11.
- 76 Mentink LF, Mackenzie MW, Toth GG *et al.* Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. *Arch Dermatol* 2006; **142**:570–6.
- 77 Werth VP, Fivenson D, Pandya AG *et al.* Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. *Arch Dermatol* 2008; **144**:25–32.
- 78 Chaidemenos G, Mourellou O, Koussidou T *et al.* An alternate-day corticosteroid regimen for pemphigus vulgaris. A 13-year prospective study. *J Eur Acad Dermatol Venereol* 2007; **21**:1386–91.
- 79 Sethy PK, Khandpur S, Sharma VK. Randomized open comparative trial of dexamethasone-cyclophosphamide pulse and daily oral cyclophosphamide versus cyclophosphamide pulse and daily oral prednisolone in pemphigus vulgaris. *Indian J Dermatol Venereol Leprol* 2009; **75**:476–82.
- 80 Hertl M, Jedlickova H, Karpati S *et al.* Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). *J Eur Acad Dermatol Venereol* 2015; **29**:405–14.
- 81 Bhat R, Sharma VK, Ramam M *et al.* Cyclophosphamide pulses with oral prednisolone in the treatment of pemphigus: a pilot study. *Dermatol Online J* 2005; **11**:4.
- 82 National Institute for Health and Care Excellence. Osteoporosis – prevention of fragility fractures. Available at: <http://cks.nice.org.uk/osteoporosis-prevention-of-fragility-fractures#!?topicsummary> (last accessed 9 August 2017).
- 83 van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. *Osteoporos Int* 2002; **13**:777–87.

- 84 Roujeau JC. Pulse glucocorticoid therapy. The 'big shot' revisited. *Arch Dermatol* 1996; **132**:1499–502.
- 85 Toth GG, Westerlaken BO, Eilders M *et al.* Dexamethasone pharmacokinetics after high-dose oral therapy for pemphigus. *Ann Pharmacother* 2002; **36**:1108–9.
- 86 Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. *Arch Dermatol* 1996; **132**:1435–9.
- 87 Mignogna MD, Lo Muzio L, Ruoppo E *et al.* High-dose intravenous 'pulse' methylprednisone in the treatment of severe oropharyngeal pemphigus: a pilot study. *J Oral Pathol Med* 2002; **31**:339–44.
- 88 Krakowski A, Covo J, Rozanski Z. Pemphigus vulgaris. *Arch Dermatol* 1969; **100**:117.
- 89 Wolff K, Schreiner E. [Immunosuppressive therapy of pemphigus vulgaris. Preliminary results of azathioprine (Imuran) treatment]. *Arch Klin Exp Dermatol* 1969; **235**:63–77 (in German).
- 90 van Dijk TJ, van Velde JL. Treatment of pemphigus and pemphigoid with azathioprine. *Dermatologica* 1973; **147**:179–85.
- 91 Aberer W, Wolff-Schreiner EC, Stingl G *et al.* Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up. *J Am Acad Dermatol* 1987; **16**:527–33.
- 92 Burton JL, Greaves MW, Marks J *et al.* Azathioprine in pemphigus vulgaris. *BMJ* 1970; **3**:84–6.
- 93 Roenigk HH, Deodhar S. Pemphigus treatment with azathioprine. Clinical and immunologic correlation. *Arch Dermatol* 1973; **107**:353–7.
- 94 Olszewska M, Kolacinska-Strasz Z, Sulej J *et al.* Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (cyclosporin) as adjuvant drugs in pemphigus vulgaris. *Am J Clin Dermatol* 2007; **8**:85–92.
- 95 Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M *et al.* Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. *J Eur Acad Dermatol Venereol* 2013; **27**:1285–92.
- 96 Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. *Arch Dermatol* 1999; **135**:54–6.
- 97 Nousari HC, Sragovich A, Kimyai-Asadi A *et al.* Mycophenolate mofetil in autoimmune and inflammatory skin disorders. *J Am Acad Dermatol* 1999; **40**:265–8.
- 98 Mimouni D, Anhalt GJ, Cummins DL *et al.* Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. *Arch Dermatol* 2003; **139**:739–42.
- 99 Powell AM, Albert S, Al Fares S *et al.* An evaluation of the usefulness of mycophenolate mofetil in pemphigus. *Br J Dermatol* 2003; **149**:138–45.
- 100 Strowd LC, Taylor SL, Jorizzo JL *et al.* Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission. *J Am Acad Dermatol* 2011; **64**:490–4.
- 101 Nagel A, Hertl M, Eming R. B-cell-directed therapy for inflammatory skin diseases. *J Invest Dermatol* 2009; **129**:289–301.
- 102 Eming R, Nagel A, Wolff-Franke S *et al.* Rituximab exerts a dual effect in pemphigus vulgaris. *J Invest Dermatol* 2008; **128**:2850–8.
- 103 Ahmed AR, Shetty S. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. *Autoimmun Rev* 2015; **14**:323–31.
- 104 Wang HH, Liu CW, Li YC *et al.* Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. *Acta Derm Venereol* 2015; **95**:928–32.
- 105 Joly P, Mouquet H, Roujeau JC *et al.* A single cycle of rituximab for the treatment of severe pemphigus. *N Engl J Med* 2007; **357**:545–52.
- 106 Craythorne EE, Mufti G, DuVivier AW. Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. *J Am Acad Dermatol* 2011; **65**:1064–5.
- 107 Kim JH, Kim YH, Kim MR *et al.* Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. *Br J Dermatol* 2011; **165**:646–51.
- 108 Matsukura S, Knowles SR, Walsh S *et al.* Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients. *Arch Dermatol* 2012; **148**:734–9.
- 109 Leshem YA, Hodak E, David M *et al.* Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. *J Am Acad Dermatol* 2013; **68**:404–11.
- 110 Leshem YA, David M, Hodak E *et al.* A prospective study on clinical response and cell-mediated immunity of pemphigus patients treated with rituximab. *Arch Dermatol Res* 2014; **306**:67–74.
- 111 Amber KT, Hertl M. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. *J Eur Acad Dermatol Venereol* 2015; **29**:777–82.
- 112 Horváth B, Huizinga J, Pas HH *et al.* Low-dose rituximab is effective in pemphigus. *Br J Dermatol* 2012; **166**:405–12.
- 113 Cho HH, Jin SP, Chung JH. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities. *J Eur Acad Dermatol Venereol* 2013; **28**:186–91.
- 114 Kanwar AJ, Vinay K, Sawatkar GU *et al.* Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. *Br J Dermatol* 2014; **170**:1341–9.
- 115 Heelan K, Al-Mohammed F, Smith MJ *et al.* Durable remission of pemphigus with a fixed-dose rituximab protocol. *JAMA Dermatol* 2014; **150**:703–8.
- 116 Vinay K, Kanwar AJ, Mittal A *et al.* Intralesional rituximab in the treatment of refractory oral pemphigus vulgaris. *JAMA Dermatol* 2015; **151**:878–82.
- 117 Ahmed AR, Spiegelman Z, Cavacini LA *et al.* Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. *N Engl J Med* 2006; **355**:1772–9.
- 118 Behzad M, Mobs C, Kneisel A *et al.* Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. *Br J Dermatol* 2012; **166**:844–52.
- 119 Kolesnik M, Becker E, Reinhold D *et al.* Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication. *J Eur Acad Dermatol Venereol* 2014; **28**:771–80.
- 120 Kasperkiewicz M, Shimanovich I, Meier M *et al.* Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. *Br J Dermatol* 2012; **166**:154–60.
- 121 Cianchini G, Lupi F, Masini C *et al.* Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. *J Am Acad Dermatol* 2012; **67**:617–22.
- 122 Huang A, Madan RK, Levitt J. Future therapies for pemphigus vulgaris: rituximab and beyond. *J Am Acad Dermatol* 2016; **74**:746–53.
- 123 Ellebrecht CT, Choi EJ, Allman DM *et al.* Subcutaneous velutuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. *JAMA Dermatol* 2014; **150**:1331–5.
- 124 Golberg O, Harman K. Cyclophosphamide. In: *Handbook of Systemic Drug Treatment in Dermatology* (Wakelin SH, Maibach HI, Archer CB, eds), 2nd edn. London: CRC Press, 2015; 138–46.

- 125 de Groot K, Harper L, Jayne DR *et al.* Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. *Ann Intern Med* 2009; **150**:670–80.
- 126 Guillevin L, Cordier JF, Lhote F *et al.* A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. *Arthritis Rheum* 1997; **40**:2187–98.
- 127 Harper L, Morgan MD, Walsh M *et al.* Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. *Ann Rheum Dis* 2012; **71**:955–60.
- 128 Lapraik C, Watts R, Bacon P *et al.* BSR and BHRP guidelines for the management of adults with ANCA associated vasculitis. *Rheumatology (Oxford)* 2007; **46**:1615–16.
- 129 Krain LS, Landau JW, Newcomer VD. Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid. *Arch Dermatol* 1972; **106**:657–61.
- 130 Fellner MJ, Katz JM, McCabe JB. Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris. *Arch Dermatol* 1978; **114**:889–94.
- 131 Pasricha JS, Sood VD, Minocha Y. Treatment of pemphigus with cyclophosphamide. *Br J Dermatol* 1975; **93**:573–6.
- 132 Piamphongsant T. Treatment of pemphigus with corticosteroids and cyclophosphamide. *J Dermatol* 1979; **6**:359–63.
- 133 Ahmed AR, Hombal S. Use of cyclophosphamide in azathioprine failures in pemphigus. *J Am Acad Dermatol* 1987; **17**:437–42.
- 134 Cummins DL, Mimouni D, Anhalt GJ *et al.* Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. *J Am Acad Dermatol* 2003; **49**:276–80.
- 135 Pasricha JS, Ramji G. Pulse therapy with dexamethasone-cyclophosphamide in pemphigus. *Indian J Dermatol Venereol Leprol* 1984; **50**:199–203.
- 136 Pasricha JS. Current regimen of pulse therapy for pemphigus: minor modifications, improved results. *Indian J Dermatol Venereol Leprol* 2008; **74**:217–21.
- 137 Kaur S, Kanwar AJ. Dexamethasone-cyclophosphamide pulse therapy in pemphigus. *Int J Dermatol* 1990; **29**:371–4.
- 138 Kanwar AJ, Kaur S, Thami GP. Long-term efficacy of dexamethasone-cyclophosphamide pulse therapy in pemphigus. *Dermatology* 2002; **204**:228–31.
- 139 Masood Q, Hassan I, Majid I *et al.* Dexamethasone cyclophosphamide pulse therapy in pemphigus: experience in Kashmir valley. *Indian J Dermatol Venereol Leprol* 2003; **69**:97–9.
- 140 Gokhale NR, Mahajan PM, Sule RR *et al.* Treatment of pemphigus with intravenous pulse cyclophosphamide. *Indian J Dermatol Venereol Leprol* 2003; **69**:334–7.
- 141 Sacchidanand S, Hiremath NC, Natraj HV *et al.* Dexamethasone-cyclophosphamide pulse therapy for autoimmune-vesiculobullous disorders at Victoria hospital, Bangalore. *Dermatol Online J* 2003; **9**:2.
- 142 Gupta R. Prolonged remission of pemphigus induced by dexamethasone-cyclophosphamide pulse therapy. *Indian J Dermatol Venereol Leprol* 2007; **73**:121–2.
- 143 Kandan S, Thappa DM. Outcome of dexamethasone-cyclophosphamide pulse therapy in pemphigus: a case series. *Indian J Dermatol Venereol Leprol* 2009; **75**:373–8.
- 144 Momeni AZ, Irajji F, Aminjavaheri M *et al.* The use of oral cyclophosphamide with dexamethasone pulse therapy in the treatment of pemphigus vulgaris. *J Dermatolog Treat* 2007; **18**:275–8.
- 145 Shaik F, Botha J, Aboobaker J *et al.* Corticosteroid/cyclophosphamide pulse treatment in South African patients with pemphigus. *Clin Exp Dermatol* 2010; **35**:245–50.
- 146 Saha M, Powell AM, Bhogal B *et al.* Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus. *Br J Dermatol* 2010; **162**:790–7.
- 147 Zivanovic D, Medenica L, Tanasilovic S *et al.* Dexamethasone-cyclophosphamide pulse therapy in pemphigus: a review of 72 cases. *Am J Clin Dermatol* 2010; **11**:123–9.
- 148 Jain R, Kumar B. Immediate and delayed complications of dexamethasone cyclophosphamide pulse (DCP) therapy. *J Dermatol* 2003; **30**:713–18.
- 149 Pasricha JS, Khaitan BK, Raman RS *et al.* Dexamethasone-cyclophosphamide pulse therapy for pemphigus. *Int J Dermatol* 1995; **34**:875–82.
- 150 Kumrah L, Ramam M, Shah P *et al.* Pituitary-adrenal function following dexamethasone-cyclophosphamide pulse therapy for pemphigus. *Br J Dermatol* 2001; **145**:944–8.
- 151 Czernik A, Toosi S, Bystryń JC *et al.* Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. *Autoimmunity* 2012; **45**:111–18.
- 152 Akerman L, Mimouni D, David M. Intravenous immunoglobulin for treatment of pemphigus. *Clin Rev Allergy Immunol* 2005; **29**:289–94.
- 153 Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. *Clin Exp Immunol* 2005; **142**:1–11.
- 154 Gürçan HM, Jeph S, Ahmed AR. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety. *Am J Clin Dermatol* 2010; **11**:315–26.
- 155 Amagai M, Ikeda S, Shimizu H *et al.* A randomized double-blind trial of intravenous immunoglobulin for pemphigus. *J Am Acad Dermatol* 2009; **60**:595–603.
- 156 Arnold DF, Burton J, Shine B *et al.* An 'n-of-1' placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris. *Br J Dermatol* 2009; **160**:1098–102.
- 157 Aoyama Y, Moriya C, Kamiya K *et al.* Catabolism of pemphigus foliaceus autoantibodies by high-dose IVIg therapy. *Eur J Dermatol* 2011; **21**:58–61.
- 158 Bystryń JC, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. *Autoimmunity* 2006; **39**:601–7.
- 159 Ahmed AR, Gürçan HM. Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris. *J Eur Acad Dermatol Venereol* 2011; **25**:1073–9.
- 160 Gürçan H, Mabrouk D, Razzaque Ahmed A. Management of pemphigus in pediatric patients. *Minerva Pediatr* 2011; **63**:279–91.
- 161 Lever WF, Goldberg HS. Treatment of pemphigus vulgaris with methotrexate. *Arch Dermatol* 1969; **100**:70–8.
- 162 Jablonska S, Chorzelski T, Blaszczyk M. Immunosuppressants in the treatment of pemphigus. *Br J Dermatol* 1970; **83**:315–23.
- 163 Lever WF. Methotrexate and prednisone in pemphigus vulgaris. Therapeutic results obtained in 36 patients between 1961 and 1970. *Arch Dermatol* 1972; **106**:491–7.
- 164 Piamphongsant T, Sivayathorn A. Pemphigus: combined treatment with methotrexate and prednisone. *J Med Assoc Thai* 1975; **58**:171–6.
- 165 Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. *Arch Dermatol* 1977; **113**:1236–41.
- 166 Dick SE, Werth VP. Pemphigus: a treatment update. *Autoimmunity* 2006; **39**:591–9.
- 167 Gürçan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. *Br J Dermatol* 2009; **161**:723–31.

- 168 Mashkilleysen N, Mashkilleysen AL. Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. *Acta Derm Venereol* 1988; **68**:413–21.
- 169 Smith TJ, Bystry J. Methotrexate as an adjuvant treatment for pemphigus vulgaris. *Arch Dermatol* 1999; **135**:1275–6.
- 170 Baum S, Greenberger S, Samuelov L *et al.* Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. *Eur J Dermatol* 2012; **22**:83–7.
- 171 Tran KD, Wolverton JE, Soter NA. Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients. *Br J Dermatol* 2013; **169**:916–21.
- 172 Kasperkiewicz M, Schmidt E, Zillikens D. Current therapy of the pemphigus group. *Clin Dermatol* 2012; **30**:84–94.
- 173 Piamphongsant T. Pemphigus controlled by dapsone. *Br J Dermatol* 1976; **94**:681–6.
- 174 Haim S, Friedman-Birnbaum R. Dapsone in the treatment of pemphigus vulgaris. *Dermatologica* 1978; **156**:120–3.
- 175 Barnard GF, Scharf MJ, Dagher RK. Sulfone syndrome in a patient receiving steroids for pemphigus. *Am J Gastroenterol* 1994; **89**:2057–9.
- 176 Bjarnason B, Skoglund C, Flosadottir E. Childhood pemphigus vulgaris treated with dapsone: a case report. *Pediatr Dermatol* 1998; **15**:381–3.
- 177 Tan HH, Tay YK. An unusual case of pemphigus vulgaris presenting as bilateral foot ulcers. *Clin Exp Dermatol* 2000; **25**:224–6.
- 178 Heaphy MR, Albrecht J, Werth VP. Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. *Arch Dermatol* 2005; **141**:699–702.
- 179 Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. *J Am Acad Dermatol* 1993; **28**:998–1000.
- 180 Alpsy E, Yilmaz E, Basaran E *et al.* Is the combination of tetracycline and nicotinamide therapy alone effective in pemphigus? *Arch Dermatol* 1995; **131**:1339–40.
- 181 Calebotta A, Saenz AM, Gonzalez F *et al.* Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients. *Int J Dermatol* 1999; **38**:217–21.
- 182 Gaspar ZS, Walkden V, Wojnarowska F. Minocycline is a useful adjuvant therapy for pemphigus. *Australas J Dermatol* 1996; **37**:93–5.
- 183 Ozog DM, Gogstetter DS, Scott G *et al.* Minocycline-induced hyperpigmentation in patients with pemphigus and pemphigoid. *Arch Dermatol* 2000; **136**:1133–8.
- 184 el-Darouti M, Marzouk S, Abdel Hay R *et al.* The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study. *Br J Dermatol* 2009; **161**:313–19.
- 185 Shah N, Green AR, Elgart GW *et al.* The use of chlorambucil with prednisone in the treatment of pemphigus. *J Am Acad Dermatol* 2000; **42**:85–8.
- 186 Penneys NS, Eaglstein WH, Indgin S *et al.* Gold sodium thiomalate treatment of pemphigus. *Arch Dermatol* 1973; **108**:56–60.
- 187 Sutej PG, Jorizzo JL, White W. Intramuscular gold therapy for young patients with pemphigus vulgaris: a prospective, open, clinical study utilizing a dermatologist/rheumatologist team approach. *J Eur Acad Dermatol Venereol* 1995; **5**:222–8.
- 188 Penneys NS, Eaglstein WH, Frost P. Management of pemphigus with gold compounds: a long-term follow-up report. *Arch Dermatol* 1976; **112**:185–7.
- 189 Pandya AG, Dyke C. Treatment of pemphigus with gold. *Arch Dermatol* 1998; **134**:1104–7.
- 190 Iranzo P, Alsina MM, Martinez-De Pablo I *et al.* Gold: an old drug still working in refractory pemphigus. *J Eur Acad Dermatol Venereol* 2007; **21**:902–7.
- 191 Lo Schiavo A, Sangiuliano S, Puca RV *et al.* Pemphigus and chrysotherapy: all that glitters is not gold! *Int J Dermatol* 2008; **47**:645–7.
- 192 Barthelemy H, Frappaz A, Cambazard F *et al.* Treatment of nine cases of pemphigus vulgaris with cyclosporine. *J Am Acad Dermatol* 1988; **18**:1262–6.
- 193 Alijotas J, Pedragosa R, Bosch J *et al.* Prolonged remission after cyclosporine therapy in pemphigus vulgaris: report of two young siblings. *J Am Acad Dermatol* 1990; **23**:701–3.
- 194 Rallis E, Stavropoulos P, Christofidou E *et al.* Pemphigus vulgaris with plaque-type psoriasis successfully treated with cyclosporine monotherapy. *Am J Clin Dermatol* 2011; **12**:283–4.
- 195 Ioannides D, Chrysomallis F, Bystry J. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. *Arch Dermatol* 2000; **136**:868–72.
- 196 Ruocco V, Rossi A, Argenziano G *et al.* Pathogenicity of the intercellular antibodies of pemphigus and their periodic removal from the circulation by plasmapheresis. *Br J Dermatol* 1978; **98**:237–41.
- 197 Cotterill JA, Barker DJ, Millard LG. Plasma exchange in the treatment of pemphigus vulgaris. *Br J Dermatol* 1978; **98**:243.
- 198 Meurer M, Braun-Falco O. Plasma exchange in the treatment of pemphigus vulgaris. *Br J Dermatol* 1979; **100**:231–2.
- 199 Auerbach R, Bystry J. Plasmapheresis and immunosuppressive therapy. Effect on levels of intercellular antibodies in pemphigus vulgaris. *Arch Dermatol* 1979; **115**:728–30.
- 200 Swanson DL, Dahl MV. Pemphigus vulgaris and plasma exchange: clinical and serologic studies. *J Am Acad Dermatol* 1981; **4**:325–8.
- 201 Roujeau JC, Kalis B, Lauret P *et al.* Plasma exchange in corticosteroid-resistant pemphigus. *Br J Dermatol* 1982; **106**:103–4.
- 202 Roujeau JC, Andre C, Joneau Fabre M *et al.* Plasma exchange in pemphigus. Uncontrolled study of ten patients. *Arch Dermatol* 1983; **119**:215–21.
- 203 Ruocco V, Astarita C, Pisani M. Plasmapheresis as an alternative or adjunctive therapy in problem cases of pemphigus. *Dermatologica* 1984; **168**:219–23.
- 204 Euler HH, Loffler H, Christophers E. Synchronization of plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris. *Arch Dermatol* 1987; **123**:1205–10.
- 205 Tan-Lim R, Bystry J. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. *J Am Acad Dermatol* 1990; **22**:35–40.
- 206 Søndergaard K, Carstens J, Jørgensen J *et al.* The steroid-sparing effect of long-term plasmapheresis in pemphigus. *Acta Derm Venereol* 1995; **75**:150–2.
- 207 Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. *J Am Acad Dermatol* 2000; **43**:1058–64.
- 208 Sagi L, Baum S, Gendelman V *et al.* The role of therapeutic plasma exchange in pemphigus vulgaris. *J Eur Acad Dermatol Venereol* 2011; **25**:82–6.
- 209 Guillaume JC, Roujeau JC, Morel P *et al.* Controlled study of plasma exchange in pemphigus. *Arch Dermatol* 1988; **124**:1659–63.
- 210 Bystry J. Plasmapheresis therapy of pemphigus. *Arch Dermatol* 1988; **124**:1702–4.
- 211 Blaszczyk M, Chorzelski TP, Jablonska S *et al.* Indications for future studies on the treatment of pemphigus with plasmapheresis. *Arch Dermatol* 1989; **125**:843–4.
- 212 Roujeau JC. Plasmapheresis therapy of pemphigus and bullous pemphigoid. *Semin Dermatol* 1988; **7**:195–200.

- 213 Ruocco V. Plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris: a novelty or a reappraisal? *Arch Dermatol* 1988; **124**:1716–18.
- 214 Aoyama Y, Nagasawa C, Nagai M *et al.* Severe pemphigus vulgaris: successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG. *Eur J Dermatol* 2008; **18**:557–60.
- 215 Seishima M, Shibuya Y, Kato G *et al.* Decreased factor XIII activity in a patient with subcutaneous bleeding after double filtration plasmapheresis. *Ther Apher Dial* 2009; **13**:229–31.
- 216 Ward DM. Extracorporeal photopheresis: how, when, and why. *J Clin Apheresis* 2011; **26**:276–85.
- 217 Rook AH, Heald PW, Nahass GT *et al.* Treatment of autoimmune disease with extracorporeal photochemotherapy: pemphigus vulgaris – preliminary report. *Yale J Biol Med* 1989; **62**:647–52.
- 218 Rook AH, Jegasothy BV, Heald P *et al.* Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris. *Ann Intern Med* 1990; **112**:303–5.
- 219 Gollnick HP, Owsianowski M, Taube KM *et al.* Unresponsive severe generalized pemphigus vulgaris successfully controlled by extracorporeal photopheresis. *J Am Acad Dermatol* 1993; **28**:122–4.
- 220 Azaña JM, de Misa RF, Harto A *et al.* Severe pemphigus foliaceus treated with extracorporeal photochemotherapy. *Arch Dermatol* 1997; **133**:287–9.
- 221 Wollina U, Lange D, Looks A. Short-time extracorporeal photochemotherapy in the treatment of drug-resistant autoimmune bullous diseases. *Dermatology* 1999; **198**:140–4.
- 222 Kaiser J, Kaatz M, Elsner P *et al.* Complete remission of drug-resistant pemphigus vegetans treated by extracorporeal photopheresis. *J Eur Acad Dermatol Venereol* 2007; **21**:843–4.
- 223 Sanli H, Akay BN, Ayyildiz E *et al.* Remission of severe autoimmune bullous disorders induced by long-term extracorporeal photochemotherapy. *Transfus Apher Sci* 2010; **43**:353–9.
- 224 Nishio-Lucar A, Balogun RA, Sanoff S. Therapeutic apheresis in kidney transplantation: a review of renal transplant immunobiology and current interventions with apheresis medicine. *J Clin Apher* 2013; **28**:56–63.
- 225 Ogata K, Yasuda K, Matsushita M *et al.* Successful treatment of adolescent pemphigus vulgaris by immunoadsorption method. *J Dermatol* 1999; **26**:236–9.
- 226 Lufil M, Stauber A, Mainka A *et al.* Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. *Br J Dermatol* 2003; **149**:598–605.
- 227 Schmidt E, Klinker E, Opitz A *et al.* Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. *Br J Dermatol* 2003; **148**:1222–9.
- 228 Meyersburg D, Schmidt E, Kasperkiewicz M *et al.* Immunoadsorption in dermatology. *Ther Apher Dial* 2012; **16**:311–20.
- 229 Huilgol SC, Black MM. Management of the immunobullous disorders. II Pemphigus. *Clin Exp Dermatol* 1995; **20**:283–93.
- 230 Huilgol SC, Black MM. Management of the immunobullous disorders. I Pemphigoid. *Clin Exp Dermatol* 1995; **20**:189–201.
- 231 Gach JE, Ilchysyn A. Beneficial effects of topical tacrolimus on recalcitrant erosions of pemphigus vulgaris. *Clin Exp Dermatol* 2004; **29**:271–2.
- 232 Irají F, Asilian A, Siadat AH. Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial. *J Drugs Dermatol* 2010; **9**:684–6.
- 233 Irají F, Yoosefi A. Healing effect of pilocarpine gel 4% on skin lesions of pemphigus vulgaris. *Int J Dermatol* 2006; **45**:743–6.
- 234 Irají F, Banan L. The efficacy of nicotinamide gel 4% as an adjuvant therapy in the treatment of cutaneous erosions of pemphigus vulgaris. *Dermatol Ther* 2010; **23**:308–11.
- 235 Tabrizi MN, Chams-Davatchi C, Esmaeeli N *et al.* Accelerating effects of epidermal growth factor on skin lesions of pemphigus vulgaris: a double-blind, randomized, controlled trial. *J Eur Acad Dermatol Venereol* 2007; **21**:79–84.
- 236 Akman A, Kacaroglu H, Yilmaz E *et al.* Periodontal status in patients with pemphigus vulgaris. *Oral Dis* 2008; **14**:640–3.
- 237 Thorat MS, Raju A, Pradeep AR. Pemphigus vulgaris: effects on periodontal health. *J Oral Sci* 2010; **52**:449–54.
- 238 Nazemi-Tabrizi M-J, Hatami P, Ghiassi M *et al.* Randomized trial of tacrolimus 0.1% ointment versus triamcinolone acetonide 0.1% paste in the treatment of oral pemphigus vulgaris. *Iran J Dermatol* 2012; **15**:42–6.
- 239 Hodgson TA, Malik F, Hegarty AM *et al.* Topical tacrolimus: a novel therapeutic intervention for recalcitrant labial pemphigus vulgaris. *Eur J Dermatol* 2003; **13**:142–4.
- 240 Pacor ML, Biasi D, Carletto A *et al.* [Topical cyclosporine in the treatment of oral pemphigus]. *Minerva Stomatol* 1998; **47**:183–6 (in Italian).
- 241 Goopu C, Staughton RC. Use of topical cyclosporin in oral pemphigus. *J Am Acad Dermatol* 1998; **38**:860–1.
- 242 Eisen D, Ellis CN. Topical cyclosporine for oral mucosal disorders. *J Am Acad Dermatol* 1990; **23**:1259–63.
- 243 Mignogna MD, Fortuna G, Leuci S *et al.* Adjuvant triamcinolone acetonide injections in oro-pharyngeal pemphigus vulgaris. *J Eur Acad Dermatol Venereol* 2010; **24**:1157–65.
- 244 Kumaran MS, Kanwar AJ. Efficacy of topical PGE2 in recalcitrant oral lesions of pemphigus vulgaris: a clinical trial. *J Eur Acad Dermatol Venereol* 2006; **20**:898–9.
- 245 Brown D. Demystifying the management of pemphigus. *Dermatol Nurs* 2009; **8**:9–12.
- 246 Hughes E, Van Onsalen J. *Dermatological Nursing: a Practical Guide*. Edinburgh: Churchill Livingstone, 2000.
- 247 Rees J. Understanding barrier function of the skin. *Lancet* 1999; **354**:1491–2.
- 248 Held E, Lund H, Agner T. Effect of different moisturizers on SLS-irritated human skin. *Contact Dermatitis* 2001; **44**:229–34.
- 249 Penzer R. Best practice in emollient therapy – a statement for healthcare professionals. *Dermatol Nurs* 2012; **11** (Suppl.):S1–19.
- 250 DermNet New Zealand. Available at: <https://www.dermnetnz.org/topics/potassium-permanganate/> (last accessed 9 August 2017).
- 251 Anderson I. Should potassium permanganate be used in wound care? *Nurs Times* 2003; **99**:61.
- 252 Baron S, Moss C. Caustic burn caused by potassium permanganate. *Arch Dis Child* 2003; **88**:96.
- 253 White R. Evidence for atraumatic soft silicone wound dressing use. *Wounds* 2005; **1**:104–9.
- 254 Wounds-UK. Best practice statement. Minimising trauma and pain in wound management. Available at: [http://www.wounds-uk.com/pdf/content\\_8952.pdf](http://www.wounds-uk.com/pdf/content_8952.pdf) (last accessed 9 August 2017).
- 255 National Institute for Health and Care Excellence. Pressure ulcers: prevention and management. Clinical guideline CG179. Available at: <https://www.nice.org.uk/guidance/cg179> (last accessed 9 August 2017).
- 256 McCuin JB, Hanlon T, Mutasim DF. Autoimmune bullous diseases: diagnosis and management. *Dermatol Nurs* 2006; **18**:20–5.
- 257 Kardos M, Levine D, Gürcan HM *et al.* Pemphigus vulgaris in pregnancy: analysis of current data on the management and outcomes. *Obstet Gynecol Surv* 2009; **64**:739–49.
- 258 McPherson T, Venning VV. Management of autoimmune blistering diseases in pregnancy. *Dermatol Clin* 2011; **29**:585–90.

- 259 Armenti VT, Radomski JS, Moritz MJ *et al.* Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. In: *Clinical Transplants*. Los Angeles: UCLA Tissue Typing Laboratory, 2002; 121–30.
- 260 Piontek JO, Borberg H, Sollberg S *et al.* Severe exacerbation of pemphigus vulgaris in pregnancy: successful treatment with plasma exchange. *Br J Dermatol* 2000; **143**:455–6.
- 261 Vinay K, Kanwar AJ, Sawatkar GU *et al.* Successful use of rituximab in the treatment of childhood and juvenile pemphigus. *J Am Acad Dermatol* 2014; **71**:669–75.
- 262 Connelly EA, Aber C, Kleiner G *et al.* Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment. *Pediatr Dermatol* 2007; **24**:172–6.
- 263 Fuertes I, Guilbert A, Mascaro JM Jr *et al.* Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature. *Dermatology* 2010; **221**:13–16.
- 264 Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. *Rheumatology (Oxford)* 2014; **53**:1377–85.
- 265 Gorsky M, Raviv M, Raviv E. Pemphigus vulgaris in adolescence. A case presentation and review of the literature. *Oral Surg Oral Med Oral Pathol* 1994; **77**:620–2.
- 266 National Institute for Health and Care Excellence. Corticosteroids – oral. Available at: <http://cks.nice.org.uk/corticosteroids-oral/#!scenario> (last accessed 9 August 2017).
- 267 Mabrouk D, Ahmed AR. Analysis of current therapy and clinical outcome in childhood pemphigus vulgaris. *Pediatr Dermatol* 2011; **28**:485–93.
- 268 Asarch A, Gürçan HM, Ahmed AR. A current review of juvenile pemphigus vulgaris: analysis of data on clinical outcomes. *Am J Clin Dermatol* 2010; **11**:21–33.
- 269 Schmidt E, Herzog S, Brocker EB *et al.* Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. *Br J Dermatol* 2005; **153**:449–51.
- 270 Kong HH, Prose NS, Ware RE *et al.* Successful treatment of refractory childhood pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). *Pediatr Dermatol* 2005; **22**:461–4.
- 271 Mamelak AJ, Eid MP, Cohen BA *et al.* Rituximab therapy in severe juvenile pemphigus vulgaris. *Cutis* 2007; **80**:335–40.
- 272 Kincaid L, Weinstein M. Rituximab therapy for childhood pemphigus vulgaris. *Pediatr Dermatol* 2016; **33**:e61–4.
- 273 Asarch A, Razzaque Ahmed A. Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulin therapy. *Pediatr Dermatol* 2009; **26**:197–202.
- 274 Matsuda H, Okamoto O, Kohno T *et al.* Case of juvenile pemphigus vulgaris which responded to i.v. immunoglobulin therapy. *J Dermatol* 2012; **39**:660–2.
- 275 Maruani A, Machet MC, Carlotti A *et al.* Immunostaining with antibodies to desmoglein provides the diagnosis of drug-induced pemphigus and allows prediction of outcome. *Am J Clin Pathol* 2008; **130**:369–74.
- 276 Brenner S, Srebrnik A, Goldberg I. Pemphigus can be induced by topical phenol as well as by foods and drugs that contain phenols or thiols. *J Cosmet Dermatol* 2003; **2**:161–5.
- 277 Feng S, Zhou W, Zhang J *et al.* Analysis of 6 cases of drug-induced pemphigus. *Eur J Dermatol* 2011; **21**:696–9.
- 278 Landau M, Brenner S. Histopathologic findings in drug-induced pemphigus. *Am J Dermatopathol* 1997; **19**:411–14.
- 279 Wolf R, Tamir A, Brenner S. Drug-induced versus drug-triggered pemphigus. *Dermatologica* 1991; **182**:207–10.
- 280 Ghodsi SZ, Chams-Davatchi C, Daneshpazhooh M *et al.* Quality of life and psychological status of patients with pemphigus vulgaris using Dermatology Life Quality Index and General Health Questionnaires. *J Dermatol* 2012; **39**:141–4.
- 281 Paradisi A, Sampogna F, Di Pietro C *et al.* Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools. *J Am Acad Dermatol* 2009; **60**:261–9.
- 282 David M, Weissman-Katzenelson V, Ben-Chetrit A *et al.* The usefulness of immunofluorescent tests in pemphigus patients in clinical remission. *Br J Dermatol* 1989; **120**:391–5.
- 283 Ratnam KV, Pang BK. Pemphigus in remission: value of negative direct immunofluorescence in management. *J Am Acad Dermatol* 1994; **30**:547–50.
- 284 Balighi K, Taheri A, Mansoori P *et al.* Value of direct immunofluorescence in predicting remission in pemphigus vulgaris. *Int J Dermatol* 2006; **45**:1308–11.
- 285 Daneshpazhooh M, Zafarmand Sedigh V, Balighi K *et al.* Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission. *J Am Acad Dermatol* 2016; **74**:1160–5.
- 286 Daneshpazhooh M, Asgari M, Naraghi ZS *et al.* A study on plucked hair as a substrate for direct immunofluorescence in pemphigus vulgaris. *J Eur Acad Dermatol Venerol* 2009; **23**:129–31.
- 287 Frew JW, Martin LK, Murrell DF. Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus. *Dermatol Clin* 2011; **29**:599–606.
- 288 Amagai M, Tanikawa A, Shimizu T *et al.* Japanese guidelines for the management of pemphigus. *J Dermatol* 2014; **41**:471–86.
- 289 National Health Service England. Clinical commissioning policy: rituximab for immunobullous disease. Available at: [https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2013/04/16035\\_FINAL.pdf](https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2013/04/16035_FINAL.pdf) (last accessed 9 August 2017).

## Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher's website:

**Appendix S1** Literature search strategy.

**Appendix S2** Additional details for the use of rituximab.

## Appendix

### Levels of evidence

Level of evidence	Type of evidence
1++	High-quality meta-analyses, systematic reviews of RCTs or RCTs with a very low risk of bias
1+	Well-conducted meta-analyses, systematic reviews of RCTs or RCTs with a low risk of bias
1–	Meta-analyses, systematic reviews of RCTs or RCTs with a high risk of bias <sup>a</sup>
2++	High-quality systematic reviews of case–control or cohort studies. High-quality case–control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the relationship is causal
2+	Well-conducted case–control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal
2–	Case–control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal <sup>a</sup>
3	Nonanalytical studies (for example case reports, case series)
4	Expert opinion, formal consensus

RCT, randomized controlled trial. <sup>a</sup>Studies with a level of evidence ‘–’ should not be used as a basis for making a recommendation.

### Strength of recommendation

Class	Evidence
A	At least one meta-analysis, systematic review or RCT rated as 1++, and directly applicable to the target population, or A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population and demonstrating overall consistency of results, or Evidence drawn from a NICE technology appraisal
B	A body of evidence including studies rated as 2++, directly applicable to the target population and demonstrating overall consistency of results, or Extrapolated evidence from studies rated as 1++ or 1+
C	A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results, or Extrapolated evidence from studies rated as 2++
D	Evidence level 3 or 4, or Extrapolated evidence from studies rated as 2+, or Formal consensus
D (GPP)	A good practice point (GPP) is a recommendation for best practice based on the experience of the guideline development group

RCT, randomized controlled trial; NICE, National Institute for Health and Care Excellence.